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Summary 
Objective 
Estimate societal costs relating to INR-testing for the year 2009 in Norway and the numbers 
of INR tests performed by GPs and private specialists during the periods of 2009, 2010 and 
2011. I also aim to calculate the number of INR-test-related GPs/ private specialist visit- 
reductions due to the introduction of the new oral anticoagulants (NOACs) for Norwegian 
patients for the same period. I will further examine if such reduced visits for atrial fibrillation 
patients have any impact on the cost- effectiveness of NOACs compared to Warfarin by 
evaluating their incremental net health benefit. 
Finally, I will calculate the 2013 total usage- costs for Dabigatran, Apixaban and 
Rivaroxaban, compared to using Warfarin.  
Background 
Venous Thromboembolism (VT) represents the third most common cardiovascular disease 
after myocardial infarction and stroke. Incidence rate of a first VT is estimated at 1-2 events 
per1000 person-years. Warfarin therapy is standard but hazardous and requires continuous 
INR monitoring. Replacement NOACs do not need any INR monitoring but they are 
considerably costly. Studies evaluating cost- effectiveness of NOACs compared to warfarin,  
with respect to numbers of such  reduced visits for INR- patients  are uncertain and limited. 
Methods and Data 
Quantitative Survey-based study in 2010 targeted at different Norwegian hospitals within the 
South East Regional Health Enterprise (SØ-HF), literature and internet search using different 
relevant databases. INR-test raw data for 2009-2011 was obtained from the  Norwegian 
Health Economics Administration (HELFO/ Helseøkonomiforvaltningen). New oral 
anticoagulants (NOAC) data for the period 2009-2013 was obtained from the Norwegian 
Prescription Database (NorPD/Reseptregisteret).  
Linear regression was used to estimate the trend of oral anticoagulants prior to the 
introduction of NOACs 
Results 
Estimated societal costs relating to INR testing in 2009 were about 700 million NOK. There is 
an actual increase (about 12%)  in the numbers of performed INR tests by GPs and private 
specialists between the years 2009-2011. Estimated future reduction in costs related to INR-
tests were found to be 66-86 million NOK, which are only half of such costs presented in the 
HTA-2013 report. In 2013 about 255 million NOK was used on NOACs and 79 million NOK 
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on Warfarin. Reductions in the number of GPs visits for INR –patients have insignificant  
impact on the cost effectiveness of NOACs compared to warfarin.  
 
 
 Interpretation 
 Reductions in the numbers of INR-tests/ GP visits presented in the HTA 2013 report for 
patients with atrial fibrillation were unrealistically high, which means that at the introduction 
of NOACs, the Norwegian Health Ministry should have allocated about 100 million NKR 
extra in its budget, to compensate for overestimated savings associated with reduced  doctor-
visits’costs when approving the use of NOACs in Norway.  For atrial fibrillation patients, the 
incremental net health benefits associated with reductions in the number of GPs/ private 
specialists visits due to using  NOACs in their treatment is far too small, and  has no apparent 
effect on the cost effectiveness of  NOACs compared to Warfarin.  
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1.1 Acronyms  
AF Atrial Fibrillation indicating abnormal heart 
rhythm 
CHA2DS2-VASc Risk score.  Different risk factors indicate increased risk of 
stroke among patients with atrial fibrillation. 
Total score ranges from 0 to 9, with the 
following scoring per risk factor: Congestive 
heart failure = 1, 
Hypertension = 1, Age>75 = 2, Prior 
Stroke/TIA/thromboembolism = 2, Vascular 
disease = 1, Age65-74 = 1, Diabetes mellitus = 
1,  
Sex (female) =1. 
 
DVT Deep Vein Thrombosis 
HELFO The Norwegian Health Economics 
Administration. It is a sub-ordinate institution 
directly linked to the Norwegian Directorate 
of Health. HELFO is responsible for direct 
payments to different health service 
providers,and for some reimbursement for 
certain medicines 
  
HTA Health technology assessment. Multi-
disciplinary containing a systematic review of 
the technology and an economic 
Evaluation. Implications for economic and 
policy settings and overall organizational 
consequences 
INHB  Incremental net health benefit. Difference in 
NHB between two interventions 
INR International Normalized Ratio indicating 
levels of agglutination of blood. Ideally 
between 2.0-3.0. Slight variations according to 
health state context of the patient 
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NHB  NHB Net Health Benefit. In a decision-
making process, a positive NHB suggests that 
the intervention represents good value for 
money 
 
NOACs New Oral Anticoagulants. In this study, only 
Apixaban, Rivaroxaban and Dabigatran are 
included. 
NoMA The Norwegian Medicines Agency, Approves 
the use of new drugs and their reimbursement 
costs 
PE Pulmonary Embolism 
QALY  
 
Quality-adjusted life-year. A measure of 
health outcomes combining quantity and 
quality of life by assigning to each year of life 
a weight from 1 (perfect health) to 0 (state 
judged equivalent to death) dependent 
on the individual's health related quality of life 
during that year 
TP Thrombosis Prophylaxis 
VTE Venous Thromboembolism 
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1. Aim      
 
The first aim of this study is to estimate the numbers of different International 
Normalized Ratio (INR) tests performed in Norway, and their societal costs for the 
year 2009. Based on raw-data for INR testing obtained from the Norwegian Health 
Economics Administration (HELFO/ Helseøkonomiforvaltningen), which is a sub-
ordinate institution directly linked to the Norwegian Directorate of Health. I will also 
examine any trends present in the numbers of INR tests performed by GPs and private 
specialists during the periods of 2009, 2010 and 2011. 
The second aim of this thesis is to examine whether assumed reductions in the                                                                                    
numbers of INR-tests performed per Atrial Fibrillation(AF) patient per year are 
realistic, as they were presented by the pharmaceutical industry and the Norwegian 
Knowledge Centre for the Health Services (Kunnskapssenteret) with respect to 
estimating costs associated with the introduction of different new oral anticoagulants 
(NOACs) in 2013. 
The third aim is to examine if such reduced numbers of visits for AF patients have any 
impact on the cost- effectiveness of NOACs compared to Warfarin when evaluating 
their incremental net health benefit (INHB) values. 
Key terms: International Normalized Ratio (INR), societal costs, reduced GPs/ private 
specialist costs, new oral anticoagulants (NOACs), and incremental net health benefit 
(INHB). 
2. Introduction 
This thesis is structured as follows: 
Firstly, I present overall general view relating to prevalence of cardiovascular disease 
(CVD), globally, regionally and locally. Secondly, I will focus on different forms of 
thromboembolic diseases, giving a brief description of their main causes, symptoms, 
tests and some alternative treatments in the form of warfarin and other newer oral 
thrombin inhibitors (NOACs).   Thirdly, I will focus on the role of International 
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Normalized Ratio (INR) monitoring for patients using warfarin based medication and 
estimate the total number of INR tests performed in different Norwegian hospitals, 
general practitioners (GPs) and specialists’ private on-site laboratories and other 
commercial laboratories in order to estimate INR societal costs for 2009, in Norway.  
Fourthly, based on INR raw-data obtained from the Norwegian Health Economics 
Administration (HELFO/ Helseøkonomiforvaltningen) for the years 2009, 2010 and 
2011, I will study any trends present in the numbers of INR tests performed by GPs 
and private specialists for this period. Based on data obtained from the Norwegian 
Prescription Database (NorPD) Reseptregisteret) for the period 2009-2013. I would 
then present my “reduced-GPs visits” findings and argue whether the assumed 
reductions in the numbers of INR-tests performed per Atrial Fibrillation (AF) patient 
per year are realistic, as they were presented by the pharmaceutical industry and the 
Norwegian Knowledge Centre for the Health Services (Kunnskapssenteret) with 
respect to estimating costs associated with the introduction of different new oral 
anticoagulants (NOACs) in 2013. I will further examine if such reduced numbers of 
visits for AF patients have any impact on the cost- effectiveness of NOACs compared 
to Warfarin when evaluating their incremental net health benefit (INHB) values. 
 I will finally estimate reduced visits-costs for Dabigatran, as an example, at the time 
Boehringer Ingelheim applied for Pradaxa approval. 
 
The study itself is divided into 3 sections.  
 
The first section relates to estimating the total number of INR tests performed in 
Norway and their societal costs for 2009, based on survey data collected during 2010 
in collaboration with Professor Ivar Sønbø Kristiansen at the University of Oslo, 
Department of Health Management and Health Economy (Murad, H & Kristiansen, I. 
S. 2010). 
The second section relates to identifying the numbers of INR tests performed in 2009, 
2010 and 2011 by different GPs and private specialists based on raw data obtained 
from the Norwegian Health Economics Administration (HELFO/ 
Helseøkonomiforvaltningen). Based on this I will also examine any patterns/ 
differences between the numbers of performed INR tests by GPs and private 
specialists between 2009 and 2011. 
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The third section relates to calculating any reductions of INR-tests  related number of 
GPs/ private specialist visits per Atrial Fibrillation (AF) patient per year in 2013,  and 
to estimate use- costs associated with using some of the new oral anticoagulants 
(NOAC) namely, Dabigatran, Apixaban and Rivaroxaban, compared to using 
Warfarin in 2013. Based on my calculated numbers of GPs/ private practitioners 
reduced visits for INR-patients, I will evaluate whether reduced numbers of visits for 
AF patients have any impact on the cost- effectiveness of NOACs compared to 
Warfarin when evaluating their incremental net health benefit (INHB) values as they 
appeared in the Kunnskapssenterets 2013 HTA report. This part of the study is done in 
collaboration with Torbjørn Wisløff, Associate Professor, and a co-author of the HTA 
report nr 5-2013. 
Data for this part of my study is extracted from the Norwegian Prescription Database 
(Reseptregisteret). 
 
Embolic disease is a cardiovascular disease in either arteries or veins that disrupts the 
natural flow of blood within the circulatory system, thus affecting the transport of 
blood-oxygen to different organs in the body. Both stroke and cardiovascular diseases 
(CVDs) represent major causes of disability and deaths worldwide (WHO, 2011).  
In 2009 about 17 million people died from CVDs, where over 7 million deaths were 
due to coronary heart disease and about 6.2 million deaths were due to stroke (WHO, 
2011). CVDs are expected to remain the leading cause of death (Yach D.et al., 2004)) 
with a postulated increase reaching an estimated 23.3 million by 2030. Some 
behavioral risk factors of heart diseases represent about 80% of causes leading to 
cerebrovascular disease and CVD (WHO, 2011). These include heavy smoking, 
excessive alcohol drinking, poor diet, high blood pressure and lack of physical 
activities, amongst others. Some underlying determinants of CVDs relate to genetic 
disposition, population aging, economic and social changes (Roger et al, 2012). 
Assuming similar exposures to different risk factors, Men develop CVDs about 10 
years earlier than women (Heron, 2008). 
In Europe, CVDs cause over 4 million deaths every year (47% of total deaths) and 
over 1.9 million deaths in the European Union, EU (40% of total deaths), where 
women represent about 55% and men about 43% of total CVDs deaths (WHO, 2011; 
Yach et al., 2004). 
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 Overall CVDs are estimated to cost the European Union (EU) economy about €196 
billion a year. In the EU, 54% of all costs are related to health care costs, 24% due to 
productivity losses and 22% due to the informal care of patients with CVD (OECD, 
2012). 
In Norway, statistics from the National Registry of Cardiovascular Diseases/ Hjerte- 
og karregisteret- (HKR, 2011)   indicate that annually,  about 15 000 people suffer 
from acute myocardial infarction, ca 50% of them under 74 years and about 13 000 
suffer from acute stroke, half of them under 76 years old. . In 2012, 5260 people died 
of ischemic heart disease relating to angina pectoris and myocardial infarctions, 
whereas 3180 people died as a result of a stroke. 1 out of 4 acute stroke patients had 
developed stroke earlier ( Ellekjær H & Selmer R, 2007). During the first 8 months of 
2012, 10 500 people suffered an acute myocardial infarction and about 9000 had an 
acute stroke as a main diagnosis (HKR, 2012. 
Data from the National Health Institute/ FHI shows that between 1970 and 2012, there 
is a progressive decline in the number of deaths due to both CVD and Stroke, probably 
due to better early diagnosis and modern therapies (Appendix 1, figures 1, 2, 4). No 
explicit data was found to reflect actual levels of AT incidences in Norway. 
 
The HUNT study from  Nord-Trøndelag (2006-2008) shows that about 55 000 people 
in Norway live with a stroke today and due to ageing populations, this number is 
estimated to rise to 110 000 in the year 2030 (Statens helsetilsyn). 
In 2012, 4852 people died from ischemic heart disease, representing a 38% reduction 
in the last 10 years (SSB, 2013). 
There are limited studies reflecting total costs associated with CVD prevalence, while 
social costs associated with stroke, in Norway, are estimated around 7-8 milliard 
kroner annually (Fjærtoft H & Indredavik B, 2007). 
A major risk factor attributed to onsets of stroke and other cardiovascular events is 
Atrial Fibrillation (AT), which simply means, disturbances to normal heart-rhythms. If 
untreated, complications associated with AT might lead to disability or fatal stroke. It 
affects about 1-2% of the Norwegian population and it is estimated that between (70-
82 000) patients suffer from AT (Helsedirektoratet Rapport, 04.2010). Standard 
therapy, so far, has been the use of the oral anticoagulant Warfarin. This is hazardous 
due to increased risks of bleedings since Warfarin interferes with normal blood 
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clotting mechanisms and reduces blood coagulation time, which might have severe 
health consequences. It is therefore necessary to monitor warfarin effect through an 
International Normalized Ratio test (NR), which measures prothrombin time (PT) as 
an indicator of blood clotting-process. Normally, INR range is set at (2.0-3.0). INR 
value of less than 2.0 target range increases the risk of clotting and a range value over 
3.0 increases the risk of hemorrhage.  
Such INR-test related costs are very high, representing severe burdens on national 
health budgets. IN 2009, Estimated INR-test costs in Norway were about NOK 70 
million, and societal costs associated with INR testing were estimated at about NOK 
705 million ( Kristiansen I.S, report of 30.07.2010).  
New oral anticoagulants (NOACs), including Dabigatran, Rivaroxaban and Apixaban 
are being increasingly used as replacements to warfarin therapy. These do not require 
any INR monitoring, however they are more costly to use. Issues relating to their 
specific efficacy, context of use, and reimbursement costs are widely debated and 
studied since they also have a huge burden on total health costs and national budgets. 
3. Background 
 
Different disorders of the blood vessels supplying blood to the heart, brain, lungs, arms and 
legs may be caused by atherosclerosis, heredity, hypertension and inflammations , such as 
rheumatic fever, which is  caused by streptococcal bacteria, amongst many other causes, often 
lead to myocardial infarctions and strokes in affected patients.(Heron, 2012) 
Source: http://my.clevelandclinic.org/heart/disorders/vascular/whatis.aspx (18.04.2014) 
3.1 Atherosclerosis 
 
Atherosclerosis is a condition caused by deposits of low density lipoproteins (LDP)/ fatty 
deposits/ plaques in the inner walls of blood vessels resulting in the formation of blockages/ 
clots in blood supply to either the heart or the brain causing disturbances and restrictions to 
blood flow. Such progressive thickening of blood vessels’ walls may result in different 
possible disease conditions, including amongst others, deep vein thrombosis (DVT), 
pulmonary embolism (PE) or systemic embolism (SE) and ischemic stroke (27). There are 
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different morphologies describing the usual sequence of lesion progression from Type I to 
type V lesions, depending on the levels of accumulated lipids and calcium (Stray H C, 1989). 
Symptoms may include chest pain and pressure/angina, sudden numbness in arms or legs, 
slurred speech, amongst others, which symbolizes transient ischemic attack (TIA) that may 
develop to a stroke.  
Source: http://www.mayoclinic.org/diseases-conditions/arteriosclerosis atherosclerosis/basics/symptoms/con-
20026972 ( 18.04.2014) 
The following figures below, figures1-3 show different examples of atherosclerosis: 
 
Figure 1.  Development of atheroma/ hardening of the arteries which might lead to the formation of 
blood clot/ thrombosis, that blocks blood flow and might lead to stroke or myocardial infarction. 
Source: http://www.patient.co.uk/health/preventing-cardiovascular-diseases (16.04.2014) 
                                                 
Figure 2. Micrograph of  a cardiac                                    Figure 3. Severe atherosclerosis of the aorta. 
artery showing luminal narrowing  
due to atherosclerosis.  
Source: http://en.wikipedia.org/wiki/Atherosclerosis (16.04.2014) 
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 Atherosclerosis is usually detected by angiography or ultrasound examination which displays 
diferent levels of stenosis, as shown in figure 4 below, 
    
 
Figure 4.  Doppler ultrasound of right internal Carotid artery showing about 70% stenosis due to 
plaques formation. 
Source: http://en.wikipedia.org/wiki/Atherosclerosis (accessed 02.06.2014) 
Typical treatment incorporates different forms of medications, including statins and 
anticoagulants, angioplasty, diet and exercise. 
3.2 Major manifestations of Thromboembolic disease 
 
Thromboembolism occurs when a thrombus breaks out from a blood vessel and dislodges  in 
another vessel, for example, the brain, which may result in stroke, or in the lungs, causing 
pulmonary embolism. 
Thromboembolic disease manifests itself in many forms, including Venous Thrombo 
Embolism (VTE), Non Rheumatic Atrial Fibrillation (AT), Thrombosis Prophylaxis and due 
to Mechanical Heart Valves. 
3.2.1 Venous Thromboembolism 
 
Venous thromboembolism (VTE) is a disease resulting from the formation of a thrombus in a 
vein. It includes both deep vein thrombosis (DVT) and pulmonary embolism (PE). 
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3.2.2 Deep Vein Thrombosis (DVT) 
 
DVT is a blood clot in the veins of the lower limbs/ legs and is often associated with 
pulmonary emboli develops often in the calf veins, leading to “hypoxemia”/ low 
concentration of Oxygen in the blood, and disturbances of blood flow through the circulatory 
system. Fibrin attaches to the endothelium of blood vessel causing structural blockages to 
normal blood flow. Complications can be serious and about 10% lead to pulmonary emboli. 
 Incidence, about 1: 1000. Therapy is through the use of anticoagulants or surgery) 
Source: http://en.wikipedia.org/wiki/Deep_vein_thrombosis (accessed 02.06.2014) 
 
Figure 5. Showing the development of deep vein thrombosis in the leg. 
 
Risk factors include immobility, recent surgery, coagulation abnormalities, obesity, amongst 
many others. 
Source: http://www.sirweb.org/patients/deep-vein-thrombosis/ ( accessed 07.06.2014) 
 
3.2.2 Pulmonary Embolism( PE) 
 
This is simply a blood clot in the lungs. “Thrombus  formation within the circulatory system 
that  obstructs pulmonary blood flow in the pulmonary artery or any of its branches” as shown 
in figure 6 below. 
http://heartdisease.about.com/od/lesscommonheartproblems/a/Pulmonary-Embolus.htm (accessed 07.06.2014) 
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Figure 6. Blood clot formation, and a blocked artery transporting blood to the lungs 
Source: http://www.medicinenet.com/pulmonary_embolism/article.htm ( accessed 07.06.2014) 
            :  http://www.nhs.uk/conditions/pulmonary-embolism/Pages/Introduction.aspx 
 
It is caused by a blockage to a pulmonary artery either from a clot, or occasionally from air. It 
is diagnosed by means of clinical examination, arterial blood gas measurements, chest- x ray, 
ultrasound tests and venography. Main treatment, depending on causes is through 
thrombolytic therapy using anticoagulants. About 10 % of patients die during the first hours 
of onset. 
Risk factors include hyper coagulation, for example in pregnancy, lack of physical activity 
deficiency of proteins C, S, and many other causes. Management treatment is through the use 
of anticoagulants. 
Source: http://medical-dictionary.thefreedictionary.com/pulmonary+embolism (accessed 07.06.2014) 
 
3.2.4 Non-Rheumatic Atrial Fibrillation (AF) 
 
Atrial fibrillation (AF) is an irregularity of heart beats due to increased right atrial pressure 
with a frequency of 350-480 per minute , leading to filtering of the atrio-ventricular node, 
resulting in irregular QRS complexes at irregular intervals, as shown in figure 7 below 
(Camm AJ et al., 2010). This irregularity results in an uneven blood flow and increased risk 
of blood clot formation. Clots may be carried through the blood flow causing stroke or 
systemic embolism in different parts of the body. 
There are no clear patterns of indications. Some “bouts” of fibrillation may occur at night and 
after meals or exercise. In the absence of other cardiac disease, it is often termed as “lone 
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atrial fibrillation”. It affects 1-2 % of populations in developed countries, including Norway 
(Andersen et al., 2010). It is more prevalent in men and prevalence increases in ageing 
populations, reaching about 10 %. About 65 000 Norwegians are estimated sufferers of AF 
 ( Camm AJ et al., 2010) Different risk factors include diabetes, hypertension, chronic renal 
and heart diseases, amongst many others. It may be triggered by venous thromboembolism or 
pulmonary embolism. It increases risks of ischemic stroke, and doubles “all-cause mortality” 
(Kannel WB & Benjamin EJ, 2008). Different circumstantial evidence and weak associations, 
there is an understanding of a link between venous thromboembolism and future atrial 
fibrillation (Kline et al., 2009) 
 
 
Figure 7.  ECG display of Heart beats for normal and atrial fibrillation conditions 
Source: http://medxforum.com/vb/showthread.php?803-By-Videos-Atrial-Fibrillation-made-Easy  (accessed 
07.06.2014) 
In addition to ECG, echocardiography, chest x-ray, Holter monitoring, exercise tests, and 
electrophysiology tests may be used for the diagnosis of AF. It is managed through different 
pharmacological interventions, including Beta-blockers and Calcium-channel blockers to 
control heart rate and heart rhythm, medicines to prevent blood clots, including heparin, 
aspirin, warfarin and new oral anticoagulants, such as dabigatran, rivaroxaban and apixaban. 
Acute onset of AF is managed through electrical and/ or pharmacological cardioversion using, 
for example, Amiodarone and class 1c agents, and through surgery. Therapy is often complex 
depending on the general health condition of patients and contra-indications of other diseases 
( Nieuwlaat et al., 2005; NICE, 2006). 
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3.2.5 Thrombosis Prophylaxis 
Optimal treatments and methods are uncertain. Warfarin and low molecular weight Heparins 
are used as prophylactic agents. The National Institute for Health and Clinical Excellence 
(NICE) sets up different guidelines for reducing risks of VTE. About 30 % of surgical 
patients develop VTE. Risk of fatal embolism is 1-5%. Compression Stockings are often used. 
Rivaroxaban is licensed now for use in orthopedic prophylaxis (NICE, 2010). Post operative 
DVT is often asymptomatic, and Routine use of thromboprophylaxis is recommended in 
patients over 40 years old. About 3% of orthopedic surgery patients develop DVT . Vascular 
surgery without prophylaxis gives about 20 % DVT ( Hollyoak et al., 2001) 
3.3 Warfarin 
 
 Warfarin is vitamin K antagonist and it is effective as an oral anticoagulant drug for patients 
suffering from thrombosis . It blocks the function of vitamin K clotting factors II ( 
Prothrombin), VII( Proaccelerin), IX and X ( Stuart-Prower) , thus delaying the production of 
vitamin K and clotting time. It is a racemic mixture of two active isomers ( R and S- isomers), 
with equal amounts of left- and right-handed enantiomers of a chiral molecule ( Karlsson et 
al., 2007), as shown in figure 8 below. The S- isomer  2-5 times more potent than the R-
isomer in producing an anticoagulant response ( Hirsh et al., 2003).  
 
Figure 8. Acyclic (left) and cyclic (right) tautomer forms of warfarin 
Source: http://en.wikipedia.org/wiki/Warfarin (accessed 02.05.2015) 
Its activity depends on clearance of clotting factors from the blood after administration of the 
drug and used for preventing thromboembolism through the inhibition of vitamin K epoxide 
reductase enzyme that recycles oxidized vitamin K to its reduced form after carboxylation 
activity (Ansell et al., 2008) as shown in figure 9 below. Response to warfarin is partially 
determined by polymorphysms in two genes (VKORC1 and CYP2C9) resulting in the need for 
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dose variations between  different patients (Wadelius et al., 2005). This explains, why, for 
example Afro-Americans are more resistant to warfarin, where as, American-Asians are more 
sensitive to it ( Reider et al., 2005) 
Its disadvantage relates to increased risk of some bleeding, with severe effects if not treated 
rapidly. The use of Warfarin must be monitored through INR-test to monitor therapeutic 
levels, ideally between ( 2.0- 3.0). Too high doses of warfarin would cause spontaneous 
bleeding. So at therapeutic levels, only PT/INR is affected.  
Its indications are prophylaxis and other thromboembolic complications in cardiac valve 
replacement and atrial fibrillation 
 
Figure 9. Vitamin K epoxide reductase enzyme that recycles oxidized vitamin K to its reduced form 
after carboxylation activity (Ansell et al., 2008) 
Source: http://www.ashp.org/s_ashp/docs/files/r-aboutwarfarinpart1.pdf (Accessed 02.05.2015) 
In addition to pharmacogenomics, different other factors affecting warfarin activity in the 
body may relate to age, albumin concentrations, liver dysfunction, diet with high levels of 
vitamin K, such as liver and green leafy vegetables, different disease states of liver and 
thyroid glands, and different drug interactions that may affect the metabolism of warfarin in 
the body. Life styles, including smoking, excessive drinking and exercise seem also to affect 
partial thrombin time as well. 
http://www.ashp.org/s_ashp/docs/files/r-aboutwarfarinpart1.pdf ( Accessed: 02.05.2015) 
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3.4 New Oral anticoagulants (NOACs) Dabigatran, Rivaroxaban and 
Apixaban 
 
Dabigatran, Rivaroxaban, and Apixaban are new brands of oral anticoagulants (blood 
thinners) as alternatives to Warfarin. No blood tests for international normalized ratio (INR) 
monitoring are required while offering similar results in terms of efficacy ( van Ryn et 
al.,2010;  Eerenberg et al., 2011). Dabigatran is a direct thrombin inhibitor used to prevent 
stroke for patients suffering from atrial fibrillation, deep vein thrombosis, pulmonary 
embolism and other non-heart valvular conditions.It  has a half-life of 12-14 hours with 
maximum anticoagulation effect within 2-3 hours after ingestion 
(http://www.drugs.com/pro/pradaxa.html ) 
 Dabigatran etexilate is converted by serum esterase enzyme into Dabigatran. Its target is 
Factor IIa (free and clot-bound thrombin). Through direct inhibition of thrombin, it inhibits 
the development of a thrombus by blocking the conversion of fibrinogen into fibrin; Half-time 
about 14 days. Coagulation cascades for different NOACs are shown in appendix 12. 
Approved indications for using Dabigatran: 
Atrial fibrillations, Reducing risk for myocardial infarction and systemic embolism  for 
patients with some risk factors including previous heart attacks, symptomatic heart failure, 
over 65 years old with diabetes or hypertension. Used also for reducing risk of VTE after 
knee or hip surgery.  It is offered in 2 doses 110 and 150 mg capsules.  
With respect to safety of using dabigatran vs warfarin, for the 150-mg dabigatran dose the 
annual rate of major bleeding was not different (3.11%; P=.31) compared with warfarin 
(3.36%) but was lower with the 110-mg dose (2.71%; P=.003). The rates of hemorrhagic 
stroke with the 110- and 150-mg dabigatran doses were lower than that with warfarin (0.12% 
and 0.10% vs 0.38%; P<.001). 
Source: 
http://scienceindex.com/stories/3288541/Comparative_Effectiveness_of_Dabigatran_Rivaroxaban_Apixaban_an
d_Warfarin_in_the_Management_of_Patients_With_Nonvalvular_Atrial_Fibrillation.html (accessed 
28.04.20149 ; and  http://www.mayoclinicproceedings.org/article/S0025-6196(13)00222-X/fulltext#appsec1 
(accessed 02.05.2015) 
Both Rivaroxaban and Apixaban are direct Factor Xa inhibitors used in the primary 
prevention of VTE and the prevention of stroke and systemic embolism in patients with 
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nonvalvular AF. It is also used in  the treatment of Pulmonary embolism and  deep venous 
thrombosis and for reducing the risk of recurrent DVT and PE after initial treatment.. Its 
bioavailability is 50 %.   
In 2 different studies, EINSTEIN and EINSTEIN-PE, the main safety outcome of major or 
clinically relevant non-major bleeding occurred at similar rates in both treatment arms.  In the 
continued-treatment study, 4 patients taking rivaroxaban (0.7%) and no patients taking 
placebo had non-fatal major bleeding, which was not significant ( Buller et al., 2012).  
With respect to safety of rivaroxaban vs warfarin, there was no difference between patients 
taking rivaroxaban and those taking warfarin in terms of all bleeding events (14.9% vs 14.5% 
per 100 patient-years; P=.44) and major bleeding events (3.6% vs 3.4% per 100 patient-years; 
P=.58). Rates of intracranial hemorrhage and fatal bleeding were however, less with 
rivaroxaban therapy (0.4% vs 0.8%, P=.003 and 0.5% vs 0.7%, P=.02, respectively). 
Source: http://www.mayoclinicproceedings.org/article/S0025-6196(13)00222-X/fulltext#appsec1 
In the ROCKET- AF randomized double blinded study, rivaroxaban 20 mg, once a day dose 
was compared to daily adjusted dose of warfarin ( INR 2.0- 3.0) using about 14 000 AF 
patients with non-valvular atrial fibrillation for the prevention of stroke and emboli, and the 
study concluded that rivaroxaban was just as effective as warfarin to prevent stroke and 
systemic emboli in the selected patients. In the rivaroxabn patients’ group, there were fewer 
incidents of intracranial and fatal bleedings.  
For Apixaban, rate of major bleeding per year was 1.4% compared with 1.2% with aspirin use 
in the AVERROES trial (P=.57) and 2.1% compared with 3.1% with using warfarin in the 
ARISTOTLE trial (P<.001). 
Source: http://www.mayoclinicproceedings.org/article/S0025-6196(13)00222-X/fulltext#appsec1 ( accessed 
02.05.2015) 
Comparative Properties of Warfarin, Dabigatran, Rivaroxaban, and Apixaban are given in 
appendix 13 
3.5 INR-Testing and Monitoring 
International Normalized Ratio is a standard monitoring measure for the time it takes for the 
blood to clot. It is also called prothrombin time. This is crucial for patients using anti-
coagulants due to some thromboembolic disease, such as deep vein thrombosis or atrial 
fibrillation. It gives an indication of the available levels of clotting factors.  
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Management of warfarin therapy is a challenge since the pharmacodynamics response is 
delayed and often difficult to predict. The antithrombotic effect of warfarin manifests itself 
after about the fifth day of therapy, which is dependent on the clearance of prothrombin  
(Hirsh et al., 1999). 
Both efficacy and safety of warfarin therapy depend on maintaining the patient’s INR values 
within the target range for the disease indication. INR monitoring should be performed daily, 
once the patient is started on anticoagulation therapy until the INR is within the therapeutic 
range for at least 2 consecutive days. For the therapeutic monitoring of warfarin treatment to 
be successful, one need to both measures INR values correctly, and interprets the results 
properly to monitor and maintain optimal dosage of warfarin with respect to the patient’s 
health state (Kearon, et al., 2008). 
INR has a therapeutic range, ideally between 2-3 as shown in the figure 10  below. 
It has no units. It is simply a ratio: INR = (PT Patient)/ PT Control ISI,  
where ISI = international sensitivity index 
The higher the INR value, the longer is clotting time, thus increasing potential risks of 
bleeding. The lower it is, the risk of developing a clot increases, as shown in figure 10 below.  
 
Figure 10. Graphical representation of the recommended INR therapeutic range for warfarin 
administration. 
Source: (Blann, 2003) 
http://www.bpac.org.nz/BT/2010/November/inr.aspx 
The range of (2.0- 3.0) is  recommended for the prophylaxis or treatment of venous 
thromboembolism and for the risk- reduction of systemic embolism for patients with valvular 
heart disease and atrial fibrillation.  The target range may be as low as 1.5 for people over 75 
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due to the risk of intracranial bleeding. Recommended therapeutic range for oral anticoagulant 
therapy is given in appendix 14 ( Hirsh et al., 1998) 
The Common Pathway of blood- clot formation involves both an intrinsic pathway 
representing partial thromboplastin time ( PTT), and an extrinsic pathway representing 
prothrombine time ( PT) as shown in figure 11 below 
 
 
Figure 11. Blood clotting cascade showing both intrinsic and extrinsic pathways 
Source: http://www.ashp.org/s_ashp/docs/files/r-aboutwarfarinpart1.pdf ( accessed 
30.04.2015) 
Factor X is activated, either by VIIa or tenase , to form Xa – aka prothrombinase.  Thrombin 
is factor IIa and it changes to prothrombin, as factor X is activated with calcium ions. 
Factor V is not activated until it has come into contact with thrombin itself. Thrombin will 
then activate fibrinogen to fibrin. Fibrin strands will begin to join and cross-link together  
with the help of factor  XIIIa. 
XIII is also activated by thrombin, and functions as a fibrin stabilising factor. 
http://almostadoctor.co.uk/content/systems/haematology/clotting/physiology-clotting 
Coagulation process is therefore, monitored in the laboratory through measurement of 
prothrombine time ( PT-INR), where – Plasma + Calcium + Tissue Thromboplastin 
(TF) + factors VIIa → Xa + V → IIa → CLOT 
17 
 
Source: 
(http://www.ucdenver.edu/academics/colleges/medicalschool/departments/surgery/education/GrandRounds/Doc
uments/GRpdfs/2007-2008/3-17-08%20Whitehill.pdf)  
With over anti-coagulation, where INR value is 5-9, it is recommended that warfarin therapy 
stops for few days until normal range is achieved, and vitamin K 1.0 – 2.5 mg, is administered 
orally to help reducing INR value and reduce any risk of serious bleeding. If INR value is > 9, 
without bleeding, 2.5 – 5 mg vitamin K is recommended. If major bleeding occurs, it is 
recommended with 10 mg vitamin K, and transfer to secondary care for factor IV 
replacement. 
Source: http://www.bpac.org.nz/BT/2010/November/inr.aspx 
4 Literature Review 
 
I performed a systematic literature review to get a general overview of 
thromboembolism disease, prevalence and outcomes of venous thromboembolism 
(VTE), atrial fibrillation (AF), stroke, and the different therapeutic practices of 
antithrombotic medicines, and how warfarin based treatment is monitored using INR 
testing. 
Literature search was carried out over intermittent periods during the last 3 years 
(September 2011- April 2014) using different databases, including PubMed, Cochrane 
Library (reviews), Medline, The Lancet and the Norwegian Medical Associations 
Journal/ Tidskrift for Den norske legeforening. For Tidsskrift for den norske 
legeforening, the search was restricted to papers also published in English and the 
period 2008 to 2014. For all other journals, there was no time limit. 
Different search terms were used including venous thromboembolism, embolic 
thrombosis, atrial fibrillation, warfarin, INR and INR monitoring. 
Many thousands of articles were displayed reflecting the amount of ongoing research 
in this field. A brief scan of few selected articles was made, based on title and 
relevance. Results of this search are displayed in the table below: 
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Table 1. Literature search results from different databases, based on disease manifestation and 
INR testing and monitoring. 
 VTE DVT Atrial 
fibrillation 
Pulmonary 
embolism 
Warfarin INR 
Testing 
INR 
Monitoring 
PubMed 15848 66779 49239 42291 21136 569 1535 
Cochrane 
Library 
Reviews 
169 307 198 360 261 115 78 
Medline 1575 3788 27147 30684 12953 185 541 
The Lancet 102 132 889 862 664 57 84 
Tidsskrift 
for Den 
norske 
legeforening 
8 12 126 57 256 25 28 
The low display search result in Tidsskriftet for Den norske legeforening is probably 
due to limiting the search to 5 years (2008-2014) and for articles published in English. 
In addition to the many international studies, I referred to in my description of the 
different manifestations of thromboembolism in the background section of this thesis, 
which related directly to Warfarin therapy, its monitoring and side-effects for 
treatments of thromboembolism and atrial fibrillation, for costs and patients visits 
estimates,  I will focus on reviewing a Health Technology Assessment report produced 
by Martin Connock and his colleagues ( Connock et al., 2007) for the National Health 
Services ( NHS R&D HTA Program, October 2007) and 2 different reports produced 
by the Norwegian Knowledge Centre for Health Services (Kunnskapssenteret) in 2010 
and 2013. I will also use data given in a short report that Professor Ivar Sønbø 
Kristiansen and myself produced collaboratively in 2010, and some other recent 
reports from the Norwegian Medicines Agency (NoMA/ Legemiddelverket). 
Connock and colleagues examined clinical effectiveness and cost effectiveness of 
different management’s strategies of oral anticoagulation treatment, including self-
management. 16 randomized trials were included. 2 trials included patients with AF 
only; three trials included patients with mechanical heart valves, and the rest with 
mixed indications for long-term anticoagulation therapy. They concluded that there 
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was no significant difference in monitoring the target therapeutic clotting range 
between self-administered and family doctor’s procedure.  
I used this article to examine possible additional research questions for my own study 
where therapeutic self-management was an alternative. In their findings, patient self-
management was more expensive than standard NHS management (£ 417 vs £ 122 per 
patient year), hence this option was not realistic. 
In their method evaluation report ( Metodevurdering rapport nr 22-2010), the authors 
conducted different literature studies, including 4 systematic reviews of 14 (average-
good quality) randomized controlled trials  to evaluate clinical efficacy of primary 
intravenous thrombolytic treatment for acute stroke, within 5 hours of developing 
symptoms compared to treatment without thrombolysis. They also evaluated different 
therapies for the secondary prevention of stroke including anticoagulation therapy by 
comparing warfarin with aspirin (acetylsalysic acid/ ASA) for prophylaxis of stroke, 
for patients suffering from atrial fibrillation. 2 different antiplatelet therapies were also 
examined where ASA was combined with slow-release dipyridamole as compared to 
using ASA on its own, and the second antiplatelet therapy compared ASA + 
dipyridamole  with clopidogrel monotherapy. The authors used Markov-modelling to 
evaluate treatment costs and QALYs with different treatment strategies and life-time 
costs associated with stroke. Both genders were analyzed at 50 and 70 years also, and 
were followed until death. Different sensitivity analysis was also performed. I will 
focus my review on the thrombolytic therapy only, since it is most relevant. 
 Studies of this report conclude that disability was reduced when thrombolytic 
treatment is administered within 3 hours of stroke onset, compared to no thrombolytic 
therapy. (RR 0.75 and confidence interval 95% 0.64-0.89). There was no difference in 
either treatment strategies with respect to mortality (RR 0.87, 95 % confidence interval 
1.18-0.75).  Warfarin was found to reduce risk of recurrent stroke in atrial fibrillation 
patients compared to ASA alone. Warfarin was also found to increase bleeding events 
in patients compared to ASA alone (RR 2.80, 95% confidence interval 1.70-4.80). 
Thrombolysis within 3 hours resulted in 0.24 QALYs loss compared to no 
thrombolytic treatment, and it reduced costs with a cost-effectiveness ratio of NOK 
665 000 per QALY gained (Rapport fra Kunnskapssenteret 22/2010) ; ( Wisløff et al., 
2010). 
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In their HTA report No 5-2013, the authors performed different cost- effectiveness 
analysis of the new oral anticoagulants Dabigatran, Rivaroxaban and Apixaban 
(ONACs) relative to each other and to Warfarin with respect to prevention of stroke in 
atrial fibrillation patients. Different risk-levels were developed using Markov 
modelling where assumptions relating to bleeding, stroke and myocardial infarction 
for atrial fibrillation patients were increased. They used Scandinavian registries for 
estimating different risks of events. Norwegian fees were used in estimating costs..  
The authors estimated also the  lifetime costs and effects in terms of net health benefit 
of new oral anticoagulants compared to warfarin when CHA2DS2-VASc =1 and the  
expected remaining QALYs for a 65 year old patient suffering from AF, with a 
medium risk of stroke is 13 QALYs (discounted: 9.12 QALYs) when treated with 
warfarin.  
The incremental net health benefit ( discounted) for Dabigatran 150, was 0.15, for 
Dabigatran 110, was -0.04, for Rivaroxaban  0.08, and for Apixaban  was 0.11. 
A general conclusion was that all three NOACs increased remaining quality-adjusted 
life expectancy, but total costs of using them were also increased. All three NOACs 
were likely to be cost-effective compared to warfarin, and produced significant 
reductions in intracranial bleedings as well when compared to warfarin (at 5 % CI, 
P<0.05).  For high risk patients, Dabigatran seemed to be  the most cost-effective. 
Results were, however,  inconclusive with regards to cost-effectiveness due to many 
uncertainties in their model.  
Their cost utility analysis costs were expressed in NKR and outcomes in QALYs from 
a health care perspective. Costs and effects were discounted at a discount rate of 4%. 
Probability assumptions for both ischemic stroke and bleeding were based on a 
Swedish registry, and the mean follow-up time was 1.5 years. In estimating their costs, 
both costs and effects were assumed to last until death. Three different doses of 
Dabigatran were used (110 mg, 150 ESC and 150NoMA); 5 mg for warfarin, 20 mg 
for Rivaroxaban and 5mg for Apixaban. 
The authors also assumed that patients using NOACs had 4.17 GP /private specialist 
visits per year. NoMA assumed 5 patient-visits. 
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They recommend further large scale randomized control trials, in different countries, 
for different patients’ selects in order to reduce their decision uncertainty (HTA 
Rapport fra Kunnskapssenteret No5-2013). 
In their two reports regarding reimbursement applications for Dabigatran ( Pradaxa), 
dated 22.05.2012, and  for Rivaroksaban (Xarelto), dated 22.11.2012, The Norwegian 
Medicines Agency (NoMA) assessed the suitability of  these two new oral 
anticoagulants (NOACs) with respect to blue- prescription form  authorization . 
NoMA is the official Norwegian administrative body covering pharmaceuticals and 
their approval. The drugs reimbursement scheme discussed descriptions of Dabigatran 
and Rivaroxaban, their treatment regimes, costs, clinical benefits with respect to 
relevant illnesses and epidemiology, and they positioned the two NOACs in the 
existing treatment programs and relevant alternatives. Side effects over long-term use 
were evaluated as well. NoMA also reviewed, different dosages presented and their 
pricing, and evaluated the different defined studies and their pharmacoeconomic 
analyses performed with respect to their budgetary consequences as well. 
The reimbursement application for Dabigatran was assessed only for the treatment/ 
prevention of stroke and systemic emboli (SEE) for atrial fibrillation patients 
.(Refusjonsrapport Dabigatran. NoMA, 22.05.2012) 
http://www.legemiddelverket.no/Blaa_resept_og_pris/Helseoekonomiske%20rapporter/Documents/201
2-2011/Pradaxa_atrieflimmer_2012.pdf                    
The report describes a prospective, randomized large-scale RE-LY study where either 
Dabigatran 110mg or 150mg (blind studies) were compared with adjusted dose 
warfarin (INR 2.0-3.0) (open) study involving18000 patients over 2 years. Specified 
excluding criteria related to patients with added risks and valvular atrial fibrillation.  
Reported findings indicated that Dabigatran (150mg) was better than Warfarin in 
preventing stroke and systemic emboli for same-risk patients for bleeding. Dabigatran 
(110mg) had similar effect to Warfarin.   
In their application, Boeringer-Ingelheim Pharma KG presented an 8000 (NOK) saved 
(reduction) costs with respect to INR control per patient when using Dabigatran 
instead of Warfarin. This was reduced to (3300) NOK. Other adjustments for life-
quality were included, and Dabigatran was estimated to have 22 000 (NOK) savings 
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and 0.22 QALYs per patient per survival time compared to Warfarin, and both costs 
and QALYs were discounted at 4% per year. Other cost effectiveness studies for ASA 
and for treatment/ prevention of thromboembolic disease with planned hip and knee 
replacements were referred to as well. 
Drop-rate from this study due to clinical events were 4,4% for Dabigatran 110mg, 
4,1% for Dabigatran 150mg and 3,0 % for Warfarin ( Sorensen et al., 2011) 
Table 2. Intention to treat (ITT) analysis of primary end point- first episode of stroke or 
systemic emboli for patients using Dabigatran110 mg, Dabigatran 150 mg and Warfarin. 
 
(12) Dabigatran 110 mg 
x 2  
Dabigatran 150 mg x 2  Warfarin  
Patients (randomized) 6015  6076  6022  
Stroke or systemic  
emboli 
Episode(%)1  183 
(1.54)  
134 (1.11)  202 (1.71)  
Hazard ratio over 
warfarin (95% CI)  
0.90 (0.74, 1.10)  0.65 (0.52, 0.81)  
p verdi superiority 
p verdi non-inferiority  
p = 0.2943  
p<0.0001  
p = 0.0001  
p<0.0001  
Source: 
http://www.legemiddelverket.no/Blaa_resept_og_pris/Helseoekonomiske%20rapporter/Documents/201
2-2011/Pradaxa_atrieflimmer_2012.pdf 
Rivaroxaban had approved indications for use in the prevention of venous 
thromboembolism (VTE) for patients undergoing elective hip or knee surgery, 
recurrence of VDT and lung emboli episodes in adult patients. 
Reimbursement application for Rivaroksaban was evaluated for the prevention of 
stroke and systemic emboli for atrial fibrillation patients ( Refusjonsrapport 
Rivaroksaban, NoMA, 22.11.2012) 
The ROCKET AF-study was described. The study performed was a prospective, 
randomized double-blinded study of the efficacy of 20mg daily doses of Rivaroxaban 
in comparison with adjusted dose Warfarin (INR 2.0-3.0) for 14000 patients with non-
valvular atrial fibrillation. Economic analysis included comparisons of Rivaroxaban 
with Warfarin and Dabigatran as well. Findings showed that Rivaroxaban was just as 
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effective as Warfarin, with significantly lower incidents of intracranial and fatal 
bleeding episodes in the Rivaroxaban test group . In the quality adjusted life years 
analysis, Rivaroxaban was shown to be cost effective with 231 824 (NOK), and 
similar data analysis for the «safety-on-treatment” group gave cost effective value of 
127 298 (NOK). Discount rates of 4% were used. Medicinal costs for Rivaroxaban 
were much higher than for Warfarin. There were some uncertainties with respect to 
the compliance evaluation of Rivaroxaban , and the quality of warfarin therapy given 
in the ROCKET AF study compared to the standard clinical practice.  
Table 3. Analysis of safety end- points, incidents of intracranial bleedings and fatality 
for Xarelto and Warfarin 
 Xarelto 
20mg daily dose 
15mg for patients 
with reduced 
kidney function 
Warfarin 
Therapeutic 
interval  
INR (2.0-3.0) 
Hasardratio (95 % 
KI) p-verdi  
 
Intracranial 
bleeding  
55 (0,49 )  84 (0,74 )  0,67 (0,47–0,93) 
p=0,019  
Mortality  208 (1,87 )  250 (2,21 )  0,85 (0,70–1,02) 
p=0,073  
Source: 
http://www.legemiddelverket.no/Blaa_resept_og_pris/Helseoekonomiske%20rapporter/Docu
ments/2012-2011/Xarelto_atrieflimmer_2012.pdf  
 
4.1 Research Questions 
 
After reviewing the above literature, and other relevant studies, and based on the raw- 
INR data at hand for 2009, 2010 and 2011, and NOACs data obtained from the 
Norwegian medicines agency,  the following research questions were set in this study: 
a) What was the number of INR-tests taken in  Norway in 2009 in different 
laboratories, and what were their societal costs ? 
b) How do the numbers of INR-tests at GPs’ or private specialists’ clinics vary 
between 2009 -2011?  
c) What is the trend of oral anticoagulants use for the years 2009- 2014 ? 
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d) What were the reduced INR visit-numbers and the reduced total costs for 
patients with atrial fibrillation as a main diagnosis for 2009, 2010 and 2011? 
e) Would reduced GPs visits for atrial fibrillation patients have any impact on the 
cost- effectiveness of NOACs compared to Warfarin when evaluating their 
incremental net health benefit ? 
f) What were the total use-cost for the new oral anticoagulants (OANC) 
Dabigatran, Rivaroxaban and Apixaban in 2013 compared to use-costs for 
Warfarin in 2013 ? 
g) What were the 2013 reduced- visit costs for Dabigatran  ? 
5 Methods 
 
The method section discusses the different types of empirical data gathering tools and 
techniques used for this study. According to Myers and Avison (2004, p.5) a research method 
is a “strategy of enquiry which moves from the underlying philosophical assumptions to 
research design and data collection”. 
5.1 Case study 
 
Different sets of empirical data for the 3 different sections in this thesis were collected 
differently. 
A case study is an empirical research inquiry method used when an” in-depth holistic 
investigation” is utilized to study a contemporary phenomenon within its real-life context 
(Feagin, Orum, & Sjoberg, 1991), especially when the “boundaries between phenomenon and 
its context” are not clearly defined (Yin, 1981). The case study inquiry usually relies on 
multiple sources of evidence allowing for triangulation approach when dealing with 
methodologies and data sources (Yin, 1984) and (Denzin, 1984). 
In addition to being used for early exploration of research theme, case studies may also be 
used for descriptive or explanatory purposes as well, in order to describe a specific situation, 
such as a case history, or to test explanations for why specific events have occurred by 
adopting causal inferences (Stake, 1995).  A descriptive theory better be developed before 
starting a project where either single case or multiple case applications are used (Pyecha, 
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1988). This facilitates maximizing learning effect in the short period of time available for 
conducting a study and guides data collection processes and data analysis especially when 
there are many more variables of interest than data indicates. This contrasts case study 
research with grounded theory, for example, where a theory is usually developed during / 
after research investigations is over (Yin, 1994; 2003). 
5.2 Survey 
 
Surveys are widely used methods for data collection. The mode may be telephone and face-
to-face interviews or through mail/ email. Sets of questions are usually set beforehand, and a 
sampling strategy is established. Data collection is performed and monitored, and reminders 
are often sent to encourage response from non-responders. Collected data is compiled and 
entered into a data-base, for processing and later analysis. Outcome may be investigative 
and/or exploratory. The aim of survey research is not to describe the individual sample, but 
analyze the larger data-set collected. A common error that occurs is selection bias. When two 
variables are correlated, we are able to make predictions for these two variables, in our case, 
number of INR-tests performed and their cost to the national health system ( Straus A & 
Corbin J, 1998). 
Reliability of collected data relates to its consistency, whilst validity reflects whether we are 
measuring what we want to measure. Internal validity relates to our selected sample and 
external validity reflects the extent to which we are able to extend our findings to much larger 
populations (Ragin C. C, 1999); (Weisberg H.F, 2005) 
Source: http://intqhc.oxfordjournals.org/content/14/4/329.full 
5.3  Section1 study- methodology 
 
Data collection here was done in collaboration with Professor Ivar Sønbø Kristiansen at the 
Department of Health Management and Health Economics at UiO 
To get an estimate of the INR-test numbers performed at different Norwegian hospitals, we 
focused our attention on the hospitals located in the South-East Health Region (SØ-HF), 
which is one of four regional health enterprises, established in June 2007. The South East 
Health Region comprises 11 different health enterprises with a catchment population of 
2,262,951 out of a total 4,799,252 (SSB, 2009). Assuming homogeneity of INR-test 
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application throughout different regions in Norway, an account of the INR-tests performed in 
may be indicative of total INR-test costs nationally. 
A search of the South East Regional Health Enterprise’s (SØ-HF) website was performed and 
a list of all hospital laboratories performing INR testing was compiled (Table 1).  Visits to 
each and every hospital’s website were also undertaken and key contact personnel in each 
laboratory were identified, and their email addresses were registered. Wherever specific lab 
leaders/ head bioengineers were listed, an e-mail was sent to them, in the form of a short 
survey. We outlined the type and purpose of this study and requested them to supply us with 
the numbers of INR tests performed at their laboratory in 2009, preferably divided into 
inpatients, internal outpatients (tests on patients visiting the hospital’s outpatient clinic (in 
Norwegian: poliklinikk”)  and external outpatients (test performed on blood samples sent 
from GPs or other physicians). Deviations from these INR test subdivisions were specified in 
the added comments column of the results table. 
Some laboratories had no specific contact e-mail, and we sent an email to the hospitals «post 
mottak” or similar. Here, we sent a brief e-mail asking for names and emails of lab leaders/ 
head bioengineers for further contact. Upon receiving such information, similar e-mails were 
sent to them requesting numbers of INR tests performed in their lab in 2009, as mentioned 
above. 
Reminder e-mails and subsequent telephone contact were undertaken after a period of 10 days 
requesting non-responder labs for INR test numbers. 
5.4  Section 2 study- methodology 
 
Data collection here was done in collaboration with Professor Ivar Sønbø Kristiansen at the 
Department of Health Management and Health Economics at UiO,  
To get an estimate of the unit costs and total costs associated with performing the tests in 
different contexts, the same approach for data collection was uses as for section 1. In addition, 
internet searches, and contacts with employees in the Directorate of Health, in the Regional 
Health administrations and various other people in health care related departments. 
INR tests are analyzed in a variety of laboratories: In hospitals, in GPs’ and private 
specialists’ on-site laboratories, in nursing homes and in commercial laboratories. 
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5.5 Section 3 study- methodology 
 
In collaboration with Associate Professor Torbjørn Wisløff at the Department of Health 
Management and Health Economics at UiO, relevant data here was extracted from the 
original raw data used in the previous two sections accounting for numbers of INR-test related 
contacts between INR patients and their GP/ private specialist for the years 2009, 2010 and 
2011.  
Use-cost data/  Prescriptions- data  was extracted from the Norwegian Prescription Database 
(NorPD)/ Reseptregisteret for the period 2009-2014.  For dispensed drugs in Norway. One 
may search for  data about the users of a particular drug or drug category. The data may be 
split by sex, age and geography.  
Selected search criteria: 
  Drug:  
  - B01AF02 Apixaban 
  - B01AF01Rivaroxaban 
  - B01AE07 Dabigatran etexilate 
 - B01AA03 Warfarin  
 
  Period: 2014, 2013, 2012, 2011, 2010, 2009 
 Age: All ages 
  Residence: Entire country 
  
  Gender: the numbers in the report are for Both sexes 
 
Source: Norwegian Prescription Database ( NorPD/ Reseptregisteret, (20.05.2014) 
http://www.norpd.no/Prevalens.aspx 
6 Data Description 
 
Here I give an account of the different data used in this study and the basis of using different 
numbers for cost calculations. 
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6.1 Raw Data 
 
Three sets of raw HELFO data were obtained from a senior advisor in health economics and 
financing at  Norwegian Directorate of Health in September 2013. This data displays numbers 
of patients with any medical disease diagnosis who had an INR test taken at GP or private 
specialist’s clinic, the number of patient visits according to diagnosis groups, gender and age-
groups in Norway for the years 2009, 2010 and 2011. Where multiple diseases are present, the 
patient’s main diagnosis is used to account for the total numbers of INR-tests performed per 
year. So, the data displays the number of visits and the number of patients with “710 takst” 
according to diagnosis, age groups and sex. “takst 710” is a code for INR-test “, and code       
( K 78) is for INR-tests for patients with atrial flimmer is the main diagnosis. 
 
6.2 Diagnosis Code- Categories of the raw data  
 
Diagnosis categories displayed in the data, most probably combines both, the International 
Classification of Primary Care coding (ICPC-2) and the ICD-10 coding systems. 
In health care, different standardized diagnosis codes are used to classify and identify 
different diseases and symptoms that form the basis for patient encounters. They are also used 
as decision support systems and for reimbursements. Such codes are often used parallel to 
intervention and procedure codes. Examples of such codes are ICD-10 Procedure Coding 
System, which describes the International Statistical Classification of Diseases and Related 
Health problems and it is maintained by the World Health organization (WHO, ICD. 2011). 
Another coding system is the   ICPC-2 (International Classification of primary care), which is 
an alphabetical index that describes different encounters, reasons , episodes and interventions 
offered at primary health care, thus allowing for episode-related data structuring ( WHO, 
ICPC-2. 2011); ( KITH, 2014).  
Coding systems are often revised, reflecting new and developing advances in medical 
treatments and health care interventions (Wikepedia, 02.06.2014), ( Steindel. S, 2010). 
Statistical classification groups together different medical conditions and concepts into 
categories such as pharmaceutical, and diagnostic codes. It also allows for including 
unspecified medical conditions as residual categories. Weaknesses of coding systems is that it 
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restricts medical decisions to an “hierarchical tree structures” without taking much account of 
parallel branching that might disturb main disease related focus. Interconnectivity and 
communication between different codes is not always appropriate either (Cheng et al., 2013). 
Health personnel might develop a “usability bias” depending on their preferential and 
familiarity issues associated with using only one specific coding system over many years 
Coding systems used in the raw data probably combines codes from both the ICPC-2 and the 
ICD-10 systems. I cannot justify for the C, G, I, J, L and M codes in the ICPC-2 coding-table. 
I therefore referred to them as ICD-10 codes, with relevant disease association.  
These represent only a small number of INR-test visits, so their actual significance on total 
visit-count is minimal, I would assume, even though no statistical significance testing was 
performed.  
Selection statistics from the Norwegian Prescription Database ( Reseptregisteret) use a drug 
selection based on either drug categories or the Anatomical Therapeutic Chemical 
classification system (ATC) Different levels may be selected in a tree-structure. 
A list of disease categories is presented in Appendices 4a and 4b. 
7 Data- calculations of Numbers and Costs 
 
In this section, I will perform different calculations of numbers and costs for the three 
different sections of this study, as mentioned earlier. 
7.1 Section 1 study:  Numbers of INR- tests performed in 2009 
 
Data used here is the INR-test data that was collected in 2010, as it appears in the “Report of 
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th
 May 2010: Use of INR Tests in South-East health Region, Norway 2009”. Ref:  (Murad, 
H. & Kristiansen I. S, .2010).  
The number of hospital laboratories performing INR-tests in South-East Regional Health 
Enterprise, Norway 2009 is given in (Appendix 2 and 3) 
- Laboratories marked in red did not respond to the data request 
- Number of INR tests accounted for represented the county of Østfold, with a 
population of 268 584 inhabitants in 2009, representing 1740 tests per 10 000 
populations 
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- Assuming homogeneity amongst different INR test guidelines and practices in 
Norwegian hospitals, and that Østfold county is representative for the whole 
Norwegian population, we got an estimate for the total INR tests performed in 
Norway in 2009 
Assumptions made: Norwegian population in 2009 = 4799 252 inhabitants 
Number of INR-tests performed in hospitals in 2009= 835, 202 tests 
Adjusted numbers of INR-tests performed in hospitals in 2009 = 949,091tests 
This number does not include INR-tests performed at GPs/ private specialist’s laboratories, or 
private chemistry laboratories or nursing homes. 
Number of INR-tests performed in 2009 included 250,795 as in-patients, 76,856 internal out-
patients (patients treated at the hospitals’ outpatient clinics), and 62,623 as external out-
patients (patients treated by GPs, private specialists, and in nursing homes (Murad & 
Kristiansen 2010). Some laboratories only reported the total number of test without specifying 
for which group of patients they were taken 
All hospitals in the county of Østfold, responded to our survey, so data obtained represented 
all hospital laboratories there. The total number for performed INR-tests was 46,741 in a 
population of 268,584 as of January 2009 (www.ssb.no).  
This represents 1740 tests per 10,000 populations. Assuming the INR-tests number in the 
county of Østfold is representative for the whole Norwegian population of 4,799,252, the 
estimated total number of INR tests performed in hospital laboratories during 2009 was 
835,202. Assuming that the South-East Health Region comprises 47% of the total Norwegian 
population, the Norwegian hospitals total estimate in 2009 would be 949,091. This is a 
conservative estimate.  
Source: (Kristiansen I.S, report of 30.07.2010) 
 To estimate Total numbers of INR-tests carried in Norway in 2009, the same INR-test data 
was used, which was collected in 2010, as it appears in the “Report of 30th July 2010: Societal 
Costs of INR Testing in Norway 2009”, with   permission. 
Ref: (Kristiansen I.S, report of 30.07.2010). 
Numbers for INR tests from GPs and private specialists was obtained from The Norwegian 
Health Economics Administration (HELFO), for commercial labs, numbers were obtained 
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from Fürst Medisinsk Laboratorium and Unilab/Capo. Other labs comprise  Volvat 
Medisinske Senter, Feiringklinikken, and others. We have no direct data from them. Our 
estimate is 10000 tests. 
Our estimate for the total numbers of INRtests performed in Norway in 2009 was 
1 783 202, tests as shown in the table below. 
Table 4.  Number of INR tests according to patients and laboratory type in Norway, 2009 
 
Source: (Kristiansen I.S, report of 30.07.2010). With permission 
 
7.1.1 Section 1 study:  Social Costs of INR- tests performed in 2009 
 
The costs associated with section 1 of this thesis are related to the total numbers of INR tests 
and the different types of societal costs involved.  Source: (Kristiansen I.S, report of 
30.07.2010). With permission. 
The type of costs included here are: 
Doctors consultation, taking blood sample, analysis of blood sample, patient’s travel costs, 
loss of productivity, if employed, and loss of leisure if not employed. 
Cost units 
- Cost of a doctor’s consultation was based on  consultation fee ( 229 NOK), 
number of warfarin users from Reseptregisteret for 2009 ( 86, 278 users), 
anticipated number of  GP visits for other reasons than having INR test ( 5 visits 
per year). This gives 430 000 consultations for other reasons than INR testing. 
From our previous calculations, about 1,24 million outpatients tests were 
performed ( 1 783 202 - 541 711 = 1 241 491 tests. This means that about 800 000 
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outpatient- visits were taken specifically for INR monitoring. For these outpatient 
visits, we included the consultation cost, travel costs and patient-time costs. 
- Cost of taking blood sample and sending it to lab : NOK 47.00 ( Normaltariff takst 
710a / Anon, 2009) 
- Cost of the performing the INR test  
This is a complex estimate involving reimbursement schemes for different patients 
and hospitals. Fee code 710a for outpatients per test ( NOK 4.00). 30% of total 
cost is covered by HELFO fees, therefore NOK13.33 fee was applied for all tests 
performed in hospital ( 902 000 tests.) . GPs get NOK  69.00 for on-site blood 
analysis and applies to all GP tests reimbursed by HELFO ( 902 000). 
Fürst Medisinsk Laboratorium received NOK 4.00 from HELFO and it was 
included in the 35,800 tests reported by Fürst for 2009. 
- For other labs ( 10 000 test) we used NOK69.00, since the unit costs are probably 
high compared to volume of tests performed. 
- Cost of informing patients about INR results, we used NOK 50 ( Normaltakst 1bd) 
(134000+ 37000) 
- Travel costs, NOK 50  ( 800 000 visits) 
- Productivity losses and time costs for patients, In 2009, “the average income in Norway 
NOK437 400, or NOK327 per hour assuming 1870 working hours per year 
(http://www.ssb.no/emner/historisk_statistikk/ aarbok/ht-0901-lonn.html). Adding the 
social cost of labor, the value of one hour lost production can be estimated at NOK 327 
per hour, or NOK 490.50 when using the 75% estimate. This amount was applied for the 
800 000 visits that presumably takes place for solely having a INR test taken”     
Source: (Kristiansen I.S, report of 30.07.2010). With permission. 
 
Total societal costs were therefor estimated at NOK 705 mill in 2009, which are 
considerable compared to the direct costs of the INR test itself, which were about 
NOK 70 mill. as outlined in table 5 below, 
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Table 5. Different costs of INR-testing according to cost category in Norway- 2009 
 
Source: (Kristiansen I.S, report of 30.07.2010). With permission. 
 
7.2 Section 2 study:  Numbers of INR- tests performed by GPs/ private 
specialists in 2009, 2010 and 2011 
 
Here I will extract from the raw data available, the total numbers of INR- tests, performed by 
different GPs and Private specialists in the years 2009, 2010 and 2011, and the specific INR-
tests where AF was the main diagnosis for the same period, for both males and females. 
The number of INR-tests in the raw data 2009-2011 is displayed according to “takst 710” 
code, distributed over many diagnosis types, based on one major disease diagnosis, for 
simplicity. Code ( K78) relates to INR-tests for patients with AF as a main diagnosis. 
A reimbursement bill from a doctor coded “takst 710” for two diagnoses would therefore 
count only once, based on the principal diagnosis. Age groups were grouped into different 
categories, A  0-4 years), B (5-9 years), and so on. Group “Q” is coded for 80 tear old patients 
and over. Sex of patients is coded 1 for men and 2 for women, and 9 for undisclosed gender. 
This gender- code 9 was not included in collected data especially that such patients’ numbers 
were extremely few compared to the total number of INR- GPs- visits. 
So, the data displays the number of visits  for patients with “710 takst” according to diagnosis, 
age groups and sex. (Appendix 3d, Table 3.3) and (Appendix 3e, Table 3.4). Data relating to 
atrial fibrillation patients (K78) was of most interest. 
Age grouping was not used, as only differences in the number of INR-tests performed for 
different sexes was of any interest to us in this study. 
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Table 6. Number of INR- tests taken at GPs/ private specialists clinics for the years 2009, 2010 and 2011. 
 
 
 
 
 
 
HELFO data 
7.3 Section 3 study:  Numbers of  users of Warfarin and NOACs for the 
years (2009-2014) 
 
The numbers of users of Warfarin and the NOACs for this part of my study is extracted from 
the Norwegian Prescription Database (Reseptregisteret). Since the numbers of NOACs users 
was quite small until the year 2012, I have selected these numbers, per sex, only for the years 
2013 and 2014, as shown in table 9 below. 
Table 7. The numbers of users of warfarin per gender, and the total number of users for the years          
( 2009- 2014)       
    Total Warfarin users 
Warfarin 
(B01AA03) 
2009 Female    34 605 86 318 
Male    51 713 
2010 Female    35 487 88 630 
Male    53 143 
2011 female    36 809 92 131 
 Male    55 322 
2012 Female    37 989 94 709 
 Male    56 720 
2013 Female    35 191 87 994 
Male    52 803 
2014 Female    31 041 77 750 
 Male    46 709 
Reseptregister data: 2015 
 
Year Gender Number of INR-
tests, all ages, where 
AF is the main 
diagnosis 
Total 
numbers of 
INR-tests 
per gender  
Total 
numbers of 
INR-tests 
performed for 
both sexes 
2009 Female 156315 388141 928 955 
 Male 221747 540814 
2010 Female 165212 407262 979 059 
 Male 234646 571797 
2011 Female 183871 436584 1 049 002 
 Male 260299 612418 
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Table 8. Numbers of NOACs users, all ages, both sexes for the years (2009 – 2014)  
Number of users  
oral 
Anticoagulants 
2009 2010 2011 2012 2013 2014 
Dabigatran 
Etexilate 
9 187 1168 4102 13879 15 357 
Rivaroxaban 45 191 898 1332 13423 20 792 
Apixaban 0 0 0 335 2260 8 640 
Total NOACs 
users 
54 378 2037 5434 29562 45189 
Reseptregister data: 2015 
 
 
Table 9. Numbers of NOACs users, all ages,  divided according to gender and total users for the years 
2013 and 2014  
NOACs Year gender NOACs 
users pr 
gender 
Total 
NOACs 
users 
Dabigatran 2013 Female    5 591  
Male    8 288 13 879 
2014 Female    6 028  
Male    9 329 15 357 
Rivaroxaban 2013 Female    6 073  
Male    7 350 13 423 
2014 Female    9 208  
Male    11 584 20 792 
Apixaban 2013 Female    1 222  
Male    1 038 2 260 
2014 Female    4 097  
Male    4 543 8 640 
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Table 10. Percentages of females using Warfarin for the years (2009- 2014), and females using 
NOACs for the years 2013 and 2014 
 Males Females Percentage 
Females using 
Warfarin 
Percentage 
females using 
NOACs 
2009 51 713 34 605 40,1 %  
2010 53 143 35 487 40,0 %  
2011 55 322 36 809 40,0 %  
2012 56 720 37 989 40,1 %  
2013 52 803 35 191 40,0 % 43,6 % 
 
2014 46 709 31 041 39,9 % 
 
43,2 % 
 
Reseptregister data. 
7.3.1 Section 3 study: Predicted  Numbers of  users  from linear regression 
for Warfarin usage (2004-2014) and NOACs usage ( 2009-2014) 
 
Using prescription data for warfarin usage (2004-2009) a simple linear regression was made 
to predict the number of users of oral anti coagulants per 1000. 
 
Table 11. Predicted number of  warfarin users and NOACs from linear regression for the period  
(2004- 2014) 
 Predicted 
number of 
users pr 
1000 from 
linear 
regression 
   Warfarin NOACs Total Oral 
Anticoagulants 
(Warfarin+ 
NOACs) users 
per 1000 
 
0 19,3417        19,15 , 19,15  
1 19,7975        19,85 , 19,85  
2 20,2533        20,38 , 20,38  
3 20,7091        20,88 , 20,88  
4 21,165        21,17 , 21,17  
5 21,6208        21,45 , 21,45  
6 22,0766        21,75 ,1 21,85  
7 22,5324        22,31 ,4 22,71  
8 22,9883        22,53 1,2 23,74  
9 23,4441        20,69 6,5 27,20  
10 23,8999        18,08 9,9 27,98  
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Figure 12. Total users of Oral anticoagulants per 1000 between ( 2004- 2014) 
 
7.4 Section 3 study:  estimated reduction of INR related visits to  GPs/ 
private specialists for the years (2009-2011) 
 
Based on HELFO-data for the years (2009-2011), we estimated total number of INR-test and 
number of INR-tests among those with atrial fibrillation as a primary diagnosis for male and 
female. Number of warfarin users was taken from the Norwegian prescription registry. By 
dividing number of INR tests by number of warfarin users, we get estimates of number of 
INR tests per warfarin users. If we assume that only those visits with atrial fibrillation as a 
primary diagnosis could be eliminated due to introduction of NOACs, and that patients with 
atrial fibrillation would have at least one GP visit with atrial fibrillation as primary diagnosis, 
estimated reduction in visits due to the introduction of NOACs would be between 3,3 and 4,0 
as seen in table 12 below 
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Table 12. Estimated reduction in GPs/ private specialists INR-visits for males and females for the 
years ( 2009-2011) 
HELFO data 
- The numbers of INR-tests pr warfarin user increases from 2009- 2011, regardless 
of gender. 
- Number of INR-tests pr warfarin user where AF is main diagnosis = (Number of 
INR-tests/ Number of users of warfarin) 
- Total number of INR-tests (without  AF as the main diagnosis) = (Total numbers 
of INR tests/ Total number of registered warfarin users) 
- Number of INR-tester without AF as main diagnosis = (Total numbers of INR-
tests pr warfarin user - number of INR-tests pr warfarin user). Here,  we assume 
that these visits would take place in any case, regardless of whether patients use 
warfarin or NOACs. 
- Estimated reduction in visits for AF patients = (Number of INR-tests pr warfarin 
user – 1) , Assuming that any patient would have at least one visit to his GP per 
year related to the AF diagnosis. 
-  
 
 
Year Gender Number of 
INR-tests, 
all ages, 
where AF is 
the main 
diagnosis 
Number 
of INR-
tests pr 
warfarin 
user  
where 
AF is the 
main 
diagnosis 
Total 
numbers 
of INR-
tests 
Total 
numbers 
of INR-
tests pr 
warfarin 
user 
Number 
of INR-
tester 
without 
AF as 
main 
diagnosis.) 
Estimated 
reduction 
in visits.  
2009 Female 156315 4,5 388141 11,21633 6,7 3,5 
 Male 221747 4,3 540814 10,45799 6,2 3,3 
2010 Female 165212 4,7 407262 11,47637 6,8 3,7 
 Male 234646 4,4 571797 10,75959 6,3 3,4 
2011 Female 183871 5,0 436584 11,86079 6,9 4,0 
 Male 260299 4,7 612418 11,07006 6,4 3,7 
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Table 13. Total estimated reduction in GPs/ private specialists INR-visits for the years (2009-
2011) 
Year INR – 
Users 
Norway 
2009-
2013 
INR-tests 
at GPs or 
private 
specialists 
INR –
tests  
Per 
warfarin-
user 
INR-tests 
with atrial 
fibrillation 
as main 
diagnosis 
INR-tests 
 with 
atrial 
fibrillation  
as main 
diagnosis- 
per user 
INR –tests  
Per 
warfarin-
user 
without 
atrial 
fibrillation 
Visits  
with  
NOAC 
Reduction 
in visits 
2009 86318 928 955 10,76 378109 4,38 6,38 (At 
least) 
6,4 
3,38 
2010 88630 979 059 11,04 399866 4,51 6,53 (At 
least) 
6,5 
3,51 
2011 92131 1 049002 11,38 444171 4,82 6,56 (At 
least) 
6,6 
3,82 
2012 94709        
2013 87994        
2013 
Kunnskaps- 
senteret- 
estimate,  
  13    5 8 
Boehringer 
Ingelheim 
assumptions 
in their 
application- 
Dabigatran,  
       16 
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7.4.1 Section 3 study:  Impacts of  reduced number of INR-test visits 
on the cost- effectiveness of NOACs compared to warfarin 
 
Table 14.  undiscounted and discounted reduced costs per patient per year 
Year numbers           Undiscounted        Discounted 
1 932,34 932,34 
2 932,34 896,4808 
3 932,34 862,0007 
4 932,34 828,8469 
5 932,34 796,9681 
6 932,34 766,3155 
7 932,34 736,8418 
8 932,34 708,5018 
9 932,34 681,2517 
10 932,34 655,0497 
11 932,34 629,8555 
12 932,34 605,6303 
13 932,34 582,3368 
            Total  12120,42 9682,42 
 
Discounted values =Reduced cost per patient per year/(1+0.04) )^(A9-1) 
Where A9 is the year number. 
 
Table 15.  Impact on incremental net health benefit 
Reduced cost per patient per year 932,34 
Assumed remaining (quality adjusted) life years  
expectancy 
13 
Reduced cost per lifetime 12120,42 
Reduced cost per lifetime (discounted) 9682,42 
Willingness to pay threshold (NKR) 588 000 
Impact on net benefit 0,016467 
 
Impact on net benefit =  Reduced cost per lifetime (discounted)/ 588000 
= 0,016467 
Assumed remaining (quality adjusted) life expectancy for  a 65 year patient suffering from 
atrial fibrillation, with a medium risk of developing stroke was estimated to be 13 QALYs 
when treated with warfarin ( discounted: 9.12 QALYs) 
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This estimate will not be exact, but illustrates approximately the impact of the number of 
INR-tests on the cost-effectiveness of NOACs compared to warfarin. 
Table 16.  Lifetime effects of oral anticoagulants when CHA2DS2-VASc=2  
Oral anticoagulant NHB  INHB INHB after 
including reduced 
costs of Kr 932,- 
per year 
Dabigatran 150  7.46  0.15 0.134 
Apixaban  7.42 0.11 0.094 
Dabigatran 150 ESC  7.41  0.09 0.074 
Rivaroxaban  7.40 0.08 0.064 
Warfarin  7.32   
Dabigatran 110  7.28 - 0.04 - 0.056 
Source: HTA Report nr 5-2013 
Dabigatran 110 above age 80 in NoMA and above 75 in ESC0,016 
NTB (Net health benefit given WTP of NOK 588 000 per QALY) 
INTB (Incremental net health benefit is the difference between NHB for each NOAC 
intervention and warfarin) 
 
 
7.5 Section 3 study:  Cost calculations 
 
Costs associated with calculating the number of reduced INR-tests at GPs and private 
specialists’ clinics in 2013 due to the introduction of NOACs  for the treatment of atrial 
fibrillation, given the assumption that atrial fibrillation is the patients’ main disease category,  
and that patients using NOACs need only one control visit to their doctor per year.  
 Cost per GPs visit (NOK)= 229 for 2009, 237 for 2010 and 244 for 2011 
Source: http://www.legemiddelsiden.no/default.aspx?PageID=139 
 Reduced costs per patient= (Reduction)* (Cost per GPs visit)  
 Total cost reductions= Reduced costs per patient (NOK) * number of users  
  Estimated reduced total costs by the Kunnskapsseneret = (number of 
users)*(estimated numbers of GPs visits)*(costs per visit)  
 
 Total costs for Dabigatran in 2013 (NOK) =9175*13 879     = 127 339 825 
 Total costs for Rivaroxaban in 2013 (NOK) =7966*13 423  =  106 927 618 
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 Total costs for Apixaban in 2013 (NOK) =  2260 *9345       =  21 119 700 
 
 Total costs NOACs in 2013 (NOK)                                        =  255 387 143 
 Total costs for warfarin in 2013 (NOK) =  87 994* 901       =  79 282 594 
 Total costs (NOACS and Warfarin)       =  334 669 737 
 
 Costs for Dabigatran (NOK)   
= (94 709)*(16)*(244)         =   359 679 424 
 
Table 17.  Reduced Costs due to introduction of NOACs, and reimbursement costs for 
Dabigatran, Norway 2013 
Year Cost 
per 
visit 
 
Reduced 
costs per 
patient 
Reduced 
total costs  
Reduced costs as estimated 
in the HTA 
Kunnskapssenteret 
Report 5-2013 
2009 229 774,11 66 820 139 
 
158  134  576 
 
2010 237 832,27 73 762 932 
 
168 042 480 
 
2011 244 932,34 85 89 7760 
 
179  839  712 
 
At reimbursement 
application for 
Dabigatran 
   359 679 424 
 
The formula used “in the Excel table” to calculate estimated reduced costs in the 
reimbursement application for Dabigatran: 
Number of users in 2013 *Reduction in the number of patients’ visits estimated by 
Boehringer-Ingelheim at their reimbursement application for Dabigatran *  Cost of GPs, 
private specialists visit in 2013: NOK 244 
=  92131*16*244  =                                   359 679 424 NOK 
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8 Key Findings 
 
In this section, I will presents key- results obtained for each of the different thesis sections 
that were outlined earlier 
8.1 Section 1 results 
Where the purpose of the study was to estimate the numbers of INR-tests performed in 
Norway in 2009 and their societal costs, the following results were obtained: 
Table 18. Estimated numbers of INR-tests and their estimated social costs for the year 2009 
Estimated total numbers of INR-tests 
performed in Norway in 2009 
1 783 202 tests 
Estimated societal costs associated 
with INR-testing in Norway in 2009 
NKR. 704 921 667 
 
8.2 Section 2 results 
 
Where the purpose was to estimate the number of INR-tests performed at GPs or private 
specialist between 2009-2011, the following results were obtained: 
Table 19. Estimated numbers of INR-tests for the years( 2009- 2011) 
Year INR – 
Users 
Norway 
2009-
2011 
INR-tests 
at GPs or 
private 
specialists 
INR –
tests  
Per 
warfarin-
user 
INR-tests 
with atrial 
fibrillation 
as main 
diagnosis 
INR-tests 
 with 
atrial 
fibrillation  
as main 
diagnosis- 
per user 
INR –tests  
Per 
warfarin-
user 
without 
atrial 
fibrillation 
2009 86318 928 955 10,76 378109 4,38 6,38 
2010 88630 979 059 11,04 399866 4,51 6,53 
2011 92131 1 049002 11,38 444171 4,82 6,56 
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8.3 Section 3 results 
 
Where the purpose was to calculate number of INR- reduced GPs/ private specialists due to 
the introduction of NOACs and then to examine if such reduced visits for atrial fibrillation 
patients have any impact on the cost- effectiveness of NOACs compared to Warfarin by 
evaluating their incremental net health benefit. Furthermore,  I proceeded  to calculate the 
2013 total usage- costs for Dabigatran, Apixaban and Rivaroxaban, compared to using 
Warfarin.  
 
Table 20. Estimated total reductions in INR- visits to GPs/ private specialists for the years (2009-
2011) due to the introduction of NOACs 
 
 
 
 
 
 
 
Table 21. The numbers of users of warfarin and NOACs  for the years (2009- 2014) 
Year Warfarin NOACs 
2009 86 318 54 
 
2010 88 630 378  
 
2011 92 131 
 
2 037 
 
2012 94 709 
 
5 434 
 
2013 87 994 29 562 
 
2014 77 750 
 
45 189 
 
 
 
    
Year Gender Estimated 
reduction in visits.  
Estimated total 
visits’ reductions 
 
3,38 
 
3,51 
 
3,82 
2009 Female 3,5 
 Male 3,3 
2010 Female 3,7 
 Male 3,4 
2011 Female 4,0 
 Male 3,7 
45 
 
 
Table 22. Percentages of females using Warfarin for the years (2009- 2014), and females using 
NOACs for the years 2013 and 2014 
 Males Females Percentage 
Females 
using 
Warfarin 
Percentage 
females 
using 
NOACs 
Percentage of 
females 
amongst all 
users of OAC 
2009 51 713 34 605 40,1 %  
40,1 % 
2010 53 143 35 487 40,0 %  
40,0 % 
2011 55 322 36 809 40,0 %  
40,0 % 
2012 56 720 37 989 40,1 %  
40,1 % 
2013 52 803 35 191 40,0 % 43,6 % 
 40,9 % 
2014 46 709 31 041 39,9 % 
 
43,2 % 
 
 41,1 % 
 
 
 
Table 23. Predicted number of users per 1000 for warfarin and NOACs from linear regression for the 
period (2004- 2014) 
 
 
 
 
 
 
 
Predicted 
number of 
users pr 
1000 from 
linear 
regression 
   Number 
of 
Warfarin 
Users 
per 1000 
Number 
of 
NOAC 
users 
pr 1000 
Number of 
Oral 
Anticoagulants 
(Warfarin+ 
NOACs) users 
per 1000 
0 19,3417        19,15 , 19,15 
1 19,7975        19,85 , 19,85 
2 20,2533        20,38 , 20,38 
3 20,7091        20,88 , 20,88 
4 21,165        21,17 , 21,17 
5 21,6208        21,45 , 21,45 
6 22,0766        21,75 ,10 21,85 
7 22,5324        22,31 ,40 22,71 
8 22,9883        22,53 1,21 23,74 
9 23,4441        20,69 6,51 27,20 
10 23,8999        18,08 9,90 27,98 
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Linear regression graph of warfarin users ( 2004- 2009) and predicted users for warfarin and NOACs ( 
2004- 2014) 
 
Figure 13. .linear regression graph of  observed and predicted users of oral anticoagulants per 1000 
between ( 2004- 2014) 
 
Table 24. Linear regression output for users of oral anticoagulants per 1000 
  Coefficients 
Standard 
Error t Stat P-value 
Lower 
95% 
Upper 
95% 
Intercept 19,34166 0,122686 157,6516 9,71E-09 19,00103 19,68229 
X Variable 
1 0,455827 0,040522 11,24891 0,000356 0,34332 0,568334 
 
When examining the impact of reduced number of INR-visits on the cost-effectiveness of 
NOACs compared to warfarin undiscounted and discounted reduced costs per patient per 
year, assumed remaining (quality adjusted) life expectancy for  a 65 year patient suffering 
from atrial fibrillation, with a medium risk of developing stroke was estimated to be 13 
QALYs when treated with warfarin ( discounted: 9.12 QALYs) and 4 % discount rate. 
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Table 25. Total undiscounted and discounted reduced costs per patient per year 
Assumed  remaining   
QALYs expectancy 
                       Undiscounted 
 
                       
                 Discounted 
            Total  12120,42 9682,42 
   
 
Table 26. Impact of reduced costs per patient per year on the incremental net health benefit  
Reduced cost per patient per year (NKR) 932,34 
Assumed remaining (quality adjusted) life years  expectancy 13 
Reduced cost per lifetime (NKR) 12120,42 
Reduced cost per lifetime (discounted NKR) 9682,42 
Impact on net benefit 0,016467 
 
Table 27. Incremental net health benefit for NOACS compared to Warfarin after including 
The reduced cost of NKR 932 per year, based on HELFO data, 2011  
Oral anticoagulant NHB values in 
the HTA-13 
report 
 INHB values in 
the HTA-13 report 
INHB after 
including reduced 
costs of NKR 
932,- per year 
Dabigatran 150  7.46  0.15 0.134 
Apixaban  7.42 0.11 0.094 
Dabigatran 150 ESC  7.41  0.09 0.074 
Rivaroxaban  7.40 0.08 0.064 
Warfarin  7.32   
Dabigatran 110  7.28 - 0.04 - 0.056 
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Table 28. Reduced Costs due to introduction of NOACs based on reduced numbers of GPs visits, and  
reimbursement costs for Dabigatran, Norway 2013 
Year Cost 
per 
visit 
 
Reduction 
in visits 
Reduced 
costs per 
patient 
Reduced 
total costs  
Reduced costs as estimated 
in the HTA 
Kunnskapssenteret 
Report 5-2013 
2009 229 3,38 774,11 66 820 139 
 
158 134 576 
 
2010 237 3,51 832,27 73 762 932 
 
168 042 480 
 
2011 244 3,82 932,34 85 89 7760 
 
179 839 712 
 
 
Reimbursement 
application- 
Dabigatran 
     
359 679 424 
 
 
Table 29. Total costs of NOACs and Warfarin use in 2013 (NOK) 
oral Anticoagulants 2013 Price per year 
(NOK) 
Total Cost in 2013 
(NOK) 
Warfarin 87994 901 
 
                                             
79 282 594  
 
Dabigatran Etexilate 13879 9175 
 
127 339 825  
 
Rivaroxaban 13423 7966 
 
106 927 618  
 
Apixaban 2260 9345 
 
 21 119 700  
 
All 3 NOACs   255 387 143 
Source: Norwegian Prescription Database 
http://www.reseptregisteret.no 
Report date: 29/05/2014 18:09 
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9 Analysis and Discussion  
 
Data collection for estimating the total numbers of INR test in Norway in 2009 was 
straightforward. Similar to other surveys, some respondents needed both email and telephone 
reminders before sending us their data. Response rate to our survey was 90 %, indicating 
excellent status when compared to average response rates of surveys in general (Appendix 
2a). Dillman (2000) reported that 70% response rate could be produced consistently with 
careful attention to design and question formats. Kittleson (1997) outlined the importance of 
follow up notices when performing electronic based surveys. Furthermore, he reports that an 
email survey would commonly produce 25% -30% response rates without any follow up 
(Kittleson, 1997 p. 196). Incentives and academic settings were described by Sheehan and 
McMillan (1999) as being relevant important factors for raising response rates in email based 
surveys. This relates well to our own survey, which was email based and both academic and 
scientific in nature where many scientists, doctors, health economists, policy makers, hospital 
administrators, health departments, and the pharmaceutical industry, amongst many others, 
have vested interests in proper estimates to quantify costs associated with INR testing since it 
places a great burden on annual health budgets. Holbrook et al., (2005) examined the 
relationship between surveys ‘response rate and demographic representativeness of the 
sample chosen they reported that  “lower response rates decreased demographic 
representativeness within the range examined”. This fits well with our own presumption of 
good representation between numbers of tests done at Østfold and Norway as a whole. Under 
ideal study situations, such a survey would have been done for all Hospitals in Norway. This 
would have given us a platform to do statistical significance analysis of empirical data 
collected and to, for example, examine standardized regression coefficients.  
To our knowledge, there were no other similar studies, at the time, to place the numbers of 
INR-tests performed per year in the proper economic context with respect to health 
expenditures, reimbursement costs and budgeting for subsidizing patients’ use of potentially 
good new oral anticoagulants in Norway.   
The formulation of our email request was friendly, short and explicit. We explained the 
purpose of our study and the specific data required. We addressed the email to lab chiefs, thus 
avoiding time-consuming interferences and possible delays when non-related personnel get 
involved (Appendix 11). In addition, Professor Ivar Sønbø Kristiansen has many healthy 
50 
 
professional and sustainable contacts with many people in the health sector, so our request 
was taken seriously, facilitating good response rate. 
Based on our collected data from SØ-HF, the 2009 total number of INR-test were 835,202 
tests. Complete data from Østfold county hospitals indicated 46, 741 in a population of 
268,548 (SSB, 1 January 2009). This represents an average 1740 tests per 10,000 population. 
Our collected data (Total INR-test, in Norway in 2009= 835,202) was slightly biased down 
since 2 hospitals didn’t reply to our survey. We therefore, saw it appropriate to adjust our 
estimates based on the collected data from Østfold region. This gave us a new estimated total 
INR-test number for the whole of Norway in 2009 equaling to 949,091. 
The Norwegian Health Economics Administration (HELFO) reports indicate  902,200 INR 
tests were reimbursed by HELFO during the period 1st of July 2008 through 30th of June 
2009. For the previous period, number of performed INR tests was  844 000 (source Steinar 
Mathisen, Directorate of Health, Oslo). We therefore, used 902,200 as an estimate of the total 
number of tests performed during 2009.(Kristiansen I.S, report of 30.07.2010), With 
permission. 
To calculate societal costs associated with INR testing in Norway in 2009, an estimate of total 
number of tests is required, including tests from GPs and other private specialists, commercial 
laboratories and some other labs performing INR-testing.  
The number of INR-tests according to type of patients and type of lab in Norway, in 2009 was 
estimated to be 1 783 202 tests (Table 4, page 32)  
Societal cost types were specified and based mainly on fee-schedules, not market prices, so 
actual costs may vary. Where doctors take blood samples for sending, costs were increased 
dramatically as proportions of total costs. In direct costs were difficult to estimate, so a 
“common-sense” approach is used for such estimations. 
This estimate however doesn’t take into consideration intangible costs associated payments 
form the welfare system to patients due to psychosomatic illness a result of worry and 
anxiety, and how that may affect the frequency of their contact with health personnel, 
resulting in additional costs. 
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Total societal costs for INR-testing in Norway for 2009 were estimated at NOK 704 921 667,  
Which are considerable and would probably constitute a major burden on Norwegian health-
care expenses and budgeting.  Our estimate would hopefully be recognized as an input to help 
policy makers to identify the economic implications associated with the magnitude of INR-
testing in Norway, and justify the allocation of funds to aid research, intervention programs, 
prevention and control initiatives, and to health- program evaluations within an economic 
framework. Such INR- social costs estimates may also support continued “public policy 
debates” (Segel 2006). This resonates well with the description of the burden of disease by the 
WHO, as “input to health decision making and planning” (WHO, 2010). 
Direct and indirect costs associated with an illness or an intervention is worked using a 
bottom up approach, by looking at different activities and available resources used, and 
multiplying up by unit costs. The amount of the activity is therefore an indicator of the likely 
financial cost, even if the costing hasn’t been  completed. Activities may vary, and some 
activities may be missed when performing an economic evaluation of costs, therefore, total 
societal costs associated with INR-testing in Norway may still be higher than the estimated 
costs of NOK 704 921 667 for 2009.  
One may however argue that maintaining INR values within the recommended range could 
lead to some cost offsets in health care costs by avoiding strokes, and reduced demands for 
the relatively more costly stroke care. 
A future prospective study would probably be interesting to evaluate changes of such costs 
due to the therapeutic introduction of new oral anticoagulants in the Norwegian health system.  
INR-testing and the use of Warfarin are very strongly associated to incidence and prevalence 
of atrial fibrillation. Our HELFO data collected for the years (2009-2011) show that about 
75% of all INR tests were performed for patients where AF was the main diagnosis. 
Amongst the Norwegian population, AF is registered as the most common cardiac arrhythmia, 
with a prevalence of 1.5–2% in the general population (Go AS, Hylek EM, Phillips KA, et al, 
2001 ; Camm et al., 2012). And its prevalence increases with increasing age, to about  10% 
among 75-year-olds and to about 18 % in people aged over 85 years. The prevalence is 
highest among men, around 15% by 75 years of age (Tveit et al., 2008).  This is probably due 
to the incidences of other old-age related diseases, including diabetes and hypertension 
(Kirchhof et al., 2012).  Feinberg WM, et al., (1995) reported that AF is comparable for men 
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and women, with a steep increase in women over 80, producing a higher risk of  stroke. The 
authors attribute this to” mortality displacement”, producing stronger correlation between 
atrial fibrillation and fatal strokes for men before they are 80 years old older. Camm et al., 
(2010) report that atrial fibrillation «It is somewhat higher in men than in women, and has 
increased over the past few decades”. 
Estimates of incidence and prevalence vary between different countries, and across Europe, it 
is estimated that about six million people suffer from AF (Camm et al., 2010). In a European 
hear survey, 39 % of respondents reported that AF was an underlying health condition ( 
Nieminen et al, 2006). In Denmark AF prevalence is about 4.38 per 1000 inhabitants aged 40-
89 years (Frost et al, 2005) , in Italy about 7.4 % of those aged 65+ ( Bilato et al., 2009),in the 
Netherlands, about 5.5 % of those aged 55+ ( Heeringa et al., 2006), in Portugal, about 2.5 % 
those aged 40+ ( Bonhorst et al., 2010), in Spain , about 8.5 % of those aged 60+ and in the 
UK, about 1 % prevalence ( BJHM, 2009). The prevalence of AF is expected to increase over 
time and is may be doubled in the next 50 years ( Camm et al., 2010 ; Rietbrock et al., 2008). 
A major challenge for doctors is the early diagnosis of  AF since it is silent disease having no 
clear symptoms and may therefore go undiagnosed for many patients, for a long time (Camm 
et al 2010). This means that , in practice, prevalence of AF, and subsequently its  management 
real costs are most likely to be underestimated. 
Our collected HELFO and prescription registry  data correlates INR-testing to prevelance of 
AF as a main diagnosis and to warfarin use. The data shows a gradual and steady increase of 
performed INR- tests for the years (2009-2011) for both men and women where AF was the 
main diagnosis (tables 6, 7 and 8, pages 35 and 36) . This corresponds to literature estimates 
of increased prevalence of atrial fibrillation over time. 
About 222 000 tests for men and 157 000 tests for women in 2009, compared to 260 000 for 
men and 184 000 test for women in 2011,  respectively. A similar trend is shown by the total 
number of INR-tests performed for the same period. Irrespective of main diagnosis, about 540 
000 for men and 389 000 for women in 2009 compared with 612 000 for men and 436 000 for 
women in 2011, respectively. This represents a progressive total increase of  4.1%  between 
2009 -2010, and 3.6% increase for 2010-2011. This is surprising, since one would have 
expected a slight decrease in these numbers of between 2010-2011 due to the introduction of 
new oral anticoagulants as alternatives to warfarin in some thromboembolic therapy practices 
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in 2010. This is probably due to NOACs therapies were insignificantly small at that period, 
that no change is marked. It is difficult for me to analyze this at face-value, but most probable 
contributing reasons might relate to increasing market segments of NOACs in Norway, better 
marketing strategies from manufacturers, little acceptance of doctors to start with alternative 
therapies to warfarin, or it might also reflect the reluctance of some doctors to change their 
therapy practices vis-à-vis their patients if patients conditions are stable, and if patients were 
happy with their health/ medication  status-quo. In the year 2014,  Dabigatran had 15 357 
users; Rivaroxaban had 20 792 users and Apixaban had 8640 users, so the data relating to this 
is so fresh and small that we might need to set up a new experimental design to study change 
rates in administrating the therapeutic use of NOACs in Norway in the future. 
Feinberg WM, et al., (1995) reported that AF is comparable for men and women, with a steep 
increase in women over 80. On the other hand, Tveit et al. (2008) reported that its prevalence 
is highest among men, around 15% by 75 years of age, and Camm et al., (2010) reported that 
atrial fibrillation“ is somewhat higher in men than in women, and has increased over the past 
few decades”. Comparing this to our data collected from the prescriptions registry data for 
warfarin and NOACs, ( table 10, page 37), about 40.1 % of warfarin users in 2009 were 
women, compared to 39.9 % female-users in 2014. For NOACs, 43.6 % of users in 2013 were 
females, compared to 43.2 % in 2014.  It is difficult for me to explain gender differences with 
respect to percentage use of warfarin and NOACs, but a possible explanation is that women 
were probably underdiagnosed group with respect to AF and other thromboembolic diseases , 
and that warfarin users are mainly patients that were diagnosed earlier, while NOACs users 
are patients that are diagnosed more recently. Advances in diagnostic technology and better 
detection and treatment guidelines would also have facilitated earlier and wider detection of 
thromboembolic conditions amongst women as well as men. Our oral anticoagulants’ data 
was not stratified according to different age groups as this was out of the scope of this study. 
Approximately at the same time as the introduction of NOACs, there was also a change in 
risk scoring system, from CHADS2 to CHA2DS2-VASc where different risk factors indicate 
increased risk of stroke among patients with atrial fibrillation. Total score ranges from 0 to 9. 
scoring per risk factor include : Age>75 = 2,  Vascular disease = 1, Diabetes mellitus = 1, 
Hypertension = 1, Prior Stroke/TIA/thromboembolism = 2 and sex (female) = 1. 
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CHA2DS2-VASc risk score acknowledges that women with atrial fibrillation have higher risk 
of stroke, and hence better awareness and understanding of AF amongst doctors would 
probably translate into more women being diagnosed and treated, with better outcomes for 
patients and less demand on the health- care system. 
To predict the number of users of oral anticoagulants per 1000, prescription data for warfarin 
(2004-2009) was used and a simple linear regression was made (Table 23, page 45). 
A graphical stacked area plot for users of oral anticoagulants per 1000 inhabitants  for 
warfarin and NOACs for the period ( 2004- 2014) is shown below, 
 
Figure 14. .Stacked area plot for Warfarin and NOACs for the years ( 2004- 2014) 
The graph shows an overall increase in the use of oral anticoagulants regardless of gender. 
There is a reduction of warfarin use from around 2012, probably due to newly diagnosed AF 
patients being treated with NOACs, whilst the majority of older warfarin users continued 
using warfarin. Some of those patients might also have died, thus diminishing total warfarin 
use accordingly. Limitations of this data are that it doesn’t reflect the percentage of warfarin 
users that were transferred to using NOACs. instead by their doctors. 
Output of linear regression graph (figure 13, page 46)  of  observed ( 2004- 2009) and predicted users 
of oral anticoagulants per 1000 (2004- 2014) is shown below: 
 
  Coefficients 
Standard 
Error t Stat P-value 
Lower 
95% 
Upper 
95% 
Intercept 19,34166 0,122686 157,6516 9,71E-09 19,00103 19,68229 
X Variable 
1 0,455827 0,040522 11,24891 0,000356 0,34332 0,568334 
Where the X-variable is the users per 1000 
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This means that the increase in users’ anticoagulants per year 95% coefficient is about 0.5 per 
1000 inhabitants ( 0.458). So, if we assume a ca 0.5 coefficient increase after the year 2009, 
then the red- regression line representing predicted number of users of oral anticoagulants per 
1000 inhabitants,( in figure 13) shows the expected increase in anticoagulants use over time. 
This coefficient lies in-between the lowest 95% coefficient interval ( 0.34) and the highest 
95% coefficient interval (0.56).  
For the year 2004, It was estimated 19.3 users per 1000 inhabitants of warfarin. If we add 
about 0.5 user per 1000 for each subsequent years, or in other words, 1 user per 2000, the red 
line would represent an estimated continued increase per year based on entry data between  
(2004-2009). The P- value is much lower than 0.05, indicating strong significance. 
The limitation of this data is that we used only 6 points in the linear regression. Ideally a 
minimum of 10 points better be used to give better prediction. Nevertheless, the graph shows 
an increase in oral anticoagulant use between (2004-2014), and an estimated 17 % more 
patients using oral anticoagulants than predicted. 
Addressing the relationship between cost- effectiveness of NOACs compared to warfarin, as 
described in the HTA- 2013 report, and reduced GPs/ specialists’ number of visits by AF 
patients due to the introduction of NOACs, based on HELFO-data for the years (2009-2011), 
we estimated total number of INR-tests and number of INR-tests among those with atrial 
fibrillation as a primary diagnosis for males and females. Number of warfarin users were 
taken from the Norwegian prescription registry. By dividing number of INR tests by number 
of warfarin users, we get estimates of number of INR tests per warfarin users. If we assume 
that only those visits with atrial fibrillation as a primary diagnosis could be eliminated due to 
introduction of NOACs, and that patients with atrial fibrillation would have at least one GP 
visit with atrial fibrillation as primary diagnosis, the estimated reduction in visits due to the 
introduction of NOACs would be between 3,3 and 4,0 visits (table 12, page 38). 
Using the same QALYs assumptions made in the HTA-report with respect to assumed 
remaining (quality adjusted) life expectancy for  a 65 year patient suffering from atrial 
fibrillation, with a medium risk of developing stroke was estimated to be 13 QALYs when 
treated with warfarin ( discounted: 9.12 QALYs), and where reduced cost per patient per year 
is about NKR 932, then the reduced cost per lifetime would be NKR 12 120 ( discounted: 
NKR 9682). This gives an added impact on the incremental net health benefit of  0, 0165 
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(table 26, page 47), where the impact on the incremental net health benefit = Reduced cost per 
lifetime (discounted)/ 588 000. This calculation is based on the willingness to pay threshold 
for cost-effectiveness of NOK 588 000 per QALY in the year 2011. 
In their HTA- 2013 report , the authors examined the relationship between mean incremental 
costs vs incremental effectiveness of NOACS with respect to warfarin. Their results are 
displayed as strategies along a  willingness to pay cost-effectiveness frontier line. They 
ranked their strategies according to incremental net health benefit ( INHB) , where the point 
furthest away from the WTP line is the most cost effective intervention (Appendix 17).  
Incremental net health benefit is the difference between net health benefit (NHB) for each 
NOAC intervention and warfarin. 
They conclude that all three oral anticoagulants, Dabigatran 150mg, Rivaroxaban 20 mg and 
Apixaban 5mg were cost- effective when each of them was compared to warfarin for patients 
with medium – high risk of developing stroke. When they were compared to each other, 
Dabigatran 150mg was the most cost-effective, with an INHB of  0.15, followed by 
Apixaban, with an INHB of 0.11, then Dabigatran ESC, with an INHB of 0.09. Raviraxaban 
was least cost effective, with an INHB of 0.08.  
Dabigatran 110 mg for the same risk group had  a negative INHB of  -0.04, indicating that it 
was not cost effective compared to Warfarin. 
After including the reduced cost- effect of NKR 932 per year, which is based on our HELFO 
data for 2011, The INHB for NOACs compared to Warfarin were  0.134 for Dabigatran 150, 
0.094 for Apixaban, 0.074 for Dabigatran 150 ESC, 0.064 for Rivaroxaban and – 0.056 for 
Dabigatran 110 ( table 27, page 47). 
Even though our INHB values are rough estimates, and assuming a WTP cost effectiveness 
threshold of NKR 588 000, and 13 expected remaining QALYs then we save about NKR 
9682 ( table 15, page 40), which, in theory, produces some sort of  health benefit of 0.0164 
value for a 65 year old AF patient with moderate risk of developing stroke if treated with 
warfarin. 
This means that the incremental net health benefit effects of reduced INR- visits to  GPs/ 
private specialists to such type of patients is far too small to have any effect on the cost 
effectiveness of using any of the NOACS, Dabigatran, Apixaban or Rivaroxaban as compared 
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to using Warfarin. This small benefit might however be marked somewhere else in the health 
system, for example, as reduced waiting time at the doctors office. 
 
Addressing total reduced visit-costs due to the introduction of oral anticoagulants in Norway 
in 2013, and reimbursement costs for Dabigatran in 2013, when Boehringer Ingelheim 
submitted a reimbursement report to the Norwegian Medicines Agency (NoMA) for its 
Dabigatran drug.  
An argument pharmaceutical companies use when applying for drug and reimbursements 
approvals so that expensive drugs used for chronic diseases, such as thromboembolic disease 
may be covered using the “ blå resept” arrangement, is often strongly based on economic 
evaluations, provided that health benefits are established. In the case of NOACs, shifting 
therapy types from Warfarin based, would arguably lead to reductions in the number of AF 
patients’ visits to their GPs or private specialists, and reduced costs since no INR- monitoring 
is required any longer. This monitoring process is costly, and must therefore be accounted for 
in any cost-benefit analysis. 
There is no clear consensus on the levels of such visit reductions in the literature, nor any 
figures from Norwegian data registries were found, as to the representations of AF related GP 
visits with respect to direct health care costs. Stewart et al., (2004) reports GP visits for 
British AF patients representing 12 % of UK direct health care cost, as seen below: 
 
Source: Stewart et al., 2004: reported in the atrial fibrillation awareness and risk education report, 
2010 
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The number of INR- visits per warfarin user per year vary, and range from about 9.2-16.2 ( 
(HTA Report no 5-2013) In Norway, an approximate number of “13” INR- visits is used  
(Statens legemiddelverk Refusjons rapport, 2012), compared to “ 16.2” in Swedish reports       
( Bjorholt I et al., 2007). This was the same number of visits that Boehringer Ingelheim used 
for their Dabigatran reimbursement application to the Norwegian Medicines Agency.  
For patients using NOACs, NoMA assumes they still use 5 GP/ private specialist visits per 
year. And the authors of the HTA -13 argue for the same patients using about 5 visits. 
Such reported figures in the above mentioned literature contradict our findings in this study 
where our data for patients having INR-test based on AF as their main diagnosis disease, 
show reductions of visits of  ( 3.8, 3.51 and 3.82) for the years 2009, 2010 and 2011 
respectively ( table 13, page 39). 
Reduction in INR-visits per patient per year =  
(INR tests per warfarin user with atrial fibrillation as main diagnosis – 1) , assuming that such 
patients would need a minimum of 1 visit per year to their GP for a check up. 
The estimated number of visits reductions  used in the HTA-13 Report was 8, and Boehringer 
Ingelheim used 16  visit- reductions for reimbursements costs relating to Dabigatran.  
Based on this, our findings show reduced total costs due to the introduction of NOACs are in 
the order of  NKR 67 mill for 2009, NKR 74 mill for 2010 and NKR 86 mill for 2011                                                                                                                                                                                                                                                                                                                                                                                              
Comparative reduced costs as estimates in the HTA-13 report. were in the order of, NKR 158 
mill for 2009, NKR 168 mill for 2010 and NKR 179 mill for 2011 . 
For Dabigatran, at reimbursement application, about NKR 340 mill reduced costs were 
estimated.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
Our assumptions were explicit in sense that visit reductions related only to one main 
diagnosis, and that only 1  GP/ private specialist’s visit is made by patients using NOACs per 
year. Such assumptions are widely open to criticism and may influence the validity and 
reliability of our findings. Bias issues were not addressed since we had no vested interests or 
strong biases to using any specific methods for either data collection or data analysis, which 
was done fairly recently in collaboration with Professor Ivar Sønbø Kristiansen and Associate 
Professor Torbjørn Wisløff at the Department of Health Economics and Health Management 
at the University of Oslo. 
59 
 
10 Conclusion  
 
Atrial fibrillation is a complex disease to diagnose and manage, depending on changing 
patients’ characteristics. It uses substantial resources across primary and secondary health 
care. Appropriate management of therapies is a key driver to reducing direct and indirect 
costs, especially in regions and times where health care resources are limited. Having well 
established guidelines, and moving practice closer to guidelines would offer patients better 
health outcomes and reduce comulative costs associated with AF. 
Societal costs associated with INR-testing in Norway for 2009 were estimated at about NKR 
705 million, which are quite substantial and place a heavy economic burden on the 
Norwegian health system. Replacing Warfarin therapy with NOACs for  atrial fibrillation 
patients would offset some of these costs, but resultant economic savings for such patients in 
terms of their reduced GPs/ private specialists visits are over-estimated in the HTA-13 report 
and by Boehringer Ingelheim. Actual reduced INR-visits for AF patients using NOACs are 
between (3-4) reduced visits. This would translate into  INR-visits economic savings in the 
order of NKR (66-86) millions, which are roughly half of the reported savings of  NKR (150-
180) millions.  In 2013, Norwegian patients used an estimated 255 million NOK on NOACs 
and 79 million NKR on Warfarin, which are considerable. Reduced visit-costs at 
reimbursement application time for Dabigatran were estimated at NOK 360 000 000, which 
were unrealisically high. 
Had the Ministry of Health accounted for this level of reduced INR visit-costs when handling 
reimbursement applications for the different new oral anticoagulants (NOACs), then about 
NOK 100 million extra should have be budgeted for at the introduction of  NOACs as 
alternative drugs to Warfarin for atrial fibrillation patients, assuming there is a total change to 
new therapies.  
Cost effectiveness for NOACs would NOT change with respect to reduced numbers of GPs/ 
private practitioners visits for INR-patients, as they appear in the HTA-13 report since the 
incremental net health benefits obtained based on such reduced INR-visits are too small, but 
the effects may however, be intangible benefits to such patients, somewhere else in the health 
system. 
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11 Limitations 
 
In addition to time limitations affecting all of us, other limitations here relate to our choice of 
data collection methodology, type of data used with respect to whether we should have used 
INR-test data for longer than 3 years period, since warfarin therapy is long established, and 
perhaps to support this by including other international data to examine any variations based 
on different cultural approaches to such therapy in different health systems. The quality of 
data registered might also be examined, with respect to its recording and maintenance in 
different health data registries. 
In our analysis, we tried our best to handle this data meticulously, and checked numbers and 
calculations over and over again to give this study good reliability and internal validity, that 
would hopefully allow us to make some generalizations with respect to our findings. 
We had extended our empirical data collected in the first and second sections of this study, 
from INR-test numbers in South-East Health Region to the larger population of all Norwegian 
hospitals and other health facilities offering INR testing. We undertook some general 
assumptions that might be questionable with respect to assuming representativeness of INR-
test practices across the country. 
Our indirect cost estimates are mostly approximates, but we deliberately biased them down 
when possible. 
There is a lack of studies to follow patients switching from warfarin to NOACs, therefore 
percentage of reduced number of GPs/ private practitioners visits as a result of changing INR- 
management is unknown. 
12 Scope for Further Work 
Our findings could open for two potential studies :- 
The first would set up an experimental design to identify possible different affordances and 
constraints within the Norwegian health system that affect moving patients on Warfarin to 
NOACs therapy for different thromboembolic chronic patients, and compare that to other 
practices in different European countries. 
The second would be draw upon cost estimates for stroke and correlate that to AF costs, and 
explore the potential of extrapolating available data to countries where no such data exists. 
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Appendices 
 
Appendix 1. 
Total number of deaths in Norway due to acute myocardial infarction, 
pulmonary embolism, cerebrovascular diseases and atherosclerosis 
for both sexes, between 45 and 84 years old. For the years 2000-2012 
 https://www.ssb.no/a/english/kortnavn/dodsarsak_en/tab-2011-10-14-01-en.html ( 
22.03.2014) 
 
 
 
 
 
 
 
 
 
  
Deaths by diseases of the circulatory system, by sex, age, cause of death, time and contents
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
Deaths Deaths Deaths Deaths Deaths Deaths Deaths Deaths Deaths Deaths Deaths Deaths Deaths
Both sexes 45-54 years Diseases of the circulatory system (I00-I99) 400 400 372 308 303 312 308 292 285 279 285 277 266
Acute myocardial infarction (I21-I22) 183 178 147 130 132 118 121 106 93 102 109 103 94
Pulmonary embolism (I26) 3 9 9 4 7 4 3 6 10 6 4 6 4
Cerebrovascular diseases (I60-I69) 82 66 62 64 51 55 52 59 62 44 54 56 46
Atherosclerosis (I70) 1 2 3 1 1 1 4 5 1 0 0 2 2
55-64 years Diseases of the circulatory system (I00-I99) 812 860 815 756 797 748 811 781 791 720 729 669 717
Acute myocardial infarction (I21-I22) 339 356 354 276 284 291 304 304 261 259 263 210 234
Pulmonary embolism (I26) 6 6 6 5 5 5 11 6 12 7 12 7 11
Cerebrovascular diseases (I60-I69) 120 160 145 115 150 123 139 129 164 129 124 128 121
Atherosclerosis (I70) 7 10 3 8 6 7 10 10 13 5 8 6 5
65-74 years Diseases of the circulatory system (I00-I99) 2463 2221 2207 1992 1807 1619 1486 1548 1435 1436 1389 1399 1420
Acute myocardial infarction (I21-I22) 930 797 821 724 607 507 488 457 492 446 412 420 404
Pulmonary embolism (I26) 22 15 21 23 26 17 12 20 20 16 17 19 24
Cerebrovascular diseases (I60-I69) 493 457 480 427 420 379 311 324 298 329 287 314 309
Atherosclerosis (I70) 43 43 50 31 32 30 23 31 31 14 33 23 27
75-84 years Diseases of the circulatory system (I00-I99) 7130 7061 6661 6042 5772 5030 4829 4628 4360 3943 3771 3524 3500
Acute myocardial infarction (I21-I22) 2146 2136 1996 1834 1767 1440 1262 1240 1199 1030 1023 906 837
Pulmonary embolism (I26) 44 58 61 66 60 39 46 46 52 37 33 35 39
Cerebrovascular diseases (I60-I69) 1848 1756 1707 1504 1454 1362 1277 1170 1206 1073 992 984 927
Atherosclerosis (I70) 142 165 125 109 109 78 99 100 84 67 57 61 62
Total 17214 16756 16045 14419 13790 12165 11596 11262 10869 9942 9602 9149 9049
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Appendix 2.  Hospital laboratories performing INR-tests in South-East Regional Health 
Enterprise, Norway 2009. Laboratories in read did not respond to the data request. 
 
1. Ahus 
2. Diakonhjemmet sykehus Laboratorium 
3. Kongsberg sykehus Laboratorium 
4. Lovisenberg Diakonale Sykehus as Klinisk kjemisk Laboratorium 
5. Martina Hansens Hospital laboratorium 
6. Oslo universitetssykehus Aker Sentrallaboratorium 
7. Oslo universitetssykehus Radiumhospitalet Sentrallaboratorium 
8. Oslo universitetssykehus Rikshospitalet Hematologisk laboratorium 
9. Oslo universitetssykehus Ullevål Laboratoriemedisinsk klinikk 
10. Oslo universitetssykehus Ullevål Medisinsk biokjemi og klinisk farmakologi 
11. Sykehuset Asker og Bærum Sentrallaboratoriet 
12. Sykehuset i Vestfold Sentrallaboratoriet 
13. Sykehuset i Vestfold Sentrallaboratorium Larvik/ Sandefjord 
14. Sykehuset Innlandet Klinisk kjemisk laboratorium Elverum 
15. Sykehuset Innlandet Klinisk kjemisk laboratorium Hamar 
16. Sykehuset Innlandet Klinisk kjemisk laboratorium Lillehammer 
17. Sykehuset Innlandet Klinisk kjemisk laboratorium Tynset 
18. Sykehuset Innlandet Laboratoriemedisin Gjøvik 
19. Sykehuset Telemark Enhet for medisinsk biokjemi og blodbank 
20. Sykehuset Telemark Kragerø Laboratorium 
21. Sykehuset Telemark Laboratorium Notodden/ Rjukan 
22. Sykehuset Østfold Sentrallaboratorium (Askim, Moss, Halden, Sarpsborg og Fredrikstad) 
23. Sørlandet sykehus HF Laboratorium Arendal 
24. Sørlandet sykehus HF Laboratorium Kristiansand 
25. Sørlandet sykehus HF Laboratorium Flekkefjord 
26. Vestre Viken HF: Sykehuset Buskerud 
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Appendix 3.  Total INR-tests_Hospitals_SØ-HF, Norway in 2009 
 
Hospital Inpatients Internal 
Outpatients 
External 
Outpatients 
Total Comments 
AHUS 22095 18314 7399 47808 All tests performed at Central Lab 
OUS Rikshospitalet 40407 9911 1076 51394 254: from different projects 
Sykehuset Innlandet: 
Gjøvik 
4776  1987 6763 Inpatients INR-tests include emergency 
and accute. 
Sykehuset Innlandet: 
Lillehammer 
31923 7709 11471 51103 External outpatients INR-tests include 
some projects 
Sykehuset Innlandet:  
Elverum 
3030 1282 1742 6054 Some outpatient INR-tests include accute 
Sykehuset Østfold HF    46741 Total numbers are for ALL labs under SØ: 
Askim, Moss, Halden, Sarpsborg og 
Fredrikstad 
Martina Hansens Hospital 614 82  696 82 :INR-tests are for all outpatients 
Vestre Viken HF: 
Sykehuset Buskerud  
12903 5742  18645  
Sykehuset i Vestfold HF: 
Sentrallaboratoriet 
14925 8914  23839 8914 :INR-tests are for all oupatients 
Sentrallaboratoriet 
Larvik/Sandefjord 
92 53 80 225 External outpatients INR-tests include 
general practitioners and institutions 
Avdeling for medisinsk 
biokjemi, Ullevål 
33484 6277 2204 41965 632 :INR-tests are unspecified and for 
research 
Hematologisk 
forskningslaboratorium, 
Ullevål 
 1414  1414 Only from outpatients 
Sørlandet Sykehus, Arendal 6883  4818 11701 4818: INR-tests for all outpatients 
Sørlandet sykehus HF, 
Kristiansand 
13081  5903 18984 5903: INR prøver for all oupatients 
Sykehuset Telemark HF, 
Skien 
9256 3715 4909 17880  
Sykehuset Telemark HF: 
Notodden 
2914 496 1285 4695 In addition, quality control tests and re-
analysis of abnormal values 
Vestre Viken HF, 
Kongsberg sykehus 
3832 922 2056 6810  
Vestre Viken HF, 
Ringerike sykehus 
   9252  
Vestre Viken HF, Asker og 
Bærum sykehus 
14000 2816 6470 23 286 2816 INR: taken at the thrombosis 
otpatient clinic  
Lovisenberg Diakonale 
sykehus 
8583 1900 3101 12584  
Sørlandet sykehus HF 
Flekkefjord 
2285 386 393 3064  
TOTAL 225083 69933 54894 404903  
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Appendix 4.  Total adjusted INR-test numbers for 2009 from different hospitals, 
according to type of patients, in South-East Regional Health Enterprise, Norway 
 
Hospital 
Nr. INR-Tests  
Inpatients  Internal 
Outpatients  
External 
Outpatients  
Total numbers  
TOTAL  250795 76856  62623  447517  
 
The Norwegian Health Economics Administration (HELFO) reports indicate  902,200 INR 
tests were reimbursed by HELFO during the period 1st of July 2008 through 30th of June 
2009. For the previous period, number of performed INR tests were  844 000 (source Steinar 
Mathisen, Directorate of Health, Oslo). We therefore, used 902,200 as an estimate of the total 
number of tests performed during 2009. 
(Kristiansen I.S, report of 30.07.2010). With permission 
Commercial laboratories 
Two commercial clinical chemistry laboratories (Fürst Medisinsk Laboratorium and 
Unilab/Capo) offered testing to doctors and institutions (source: Fürst Medisinsk 
Laboratorium). In the spring of 2010 Fürst and Unilab merged, and data on INR tests were 
therefore obtained from Fürst. Here, it was reported that the two laboratories performed in 
total 35,800 tests in 2009. This number is well in line with data from HELFO. (Kristiansen 
I.S, report of 30.07.2010). With Permission. 
Other laboratories  
Presumably, some large nursing homes, private health care providers (Volvat Medisinske 
Senter , Feiringklinikken, etc.) and various other health care institutions (rehabilitation units, 
etc.) have laboratory equipment for taking INR-tests. We have no information about the test 
volumes here, but presumably they are limited. For completeness, we assume that in total 
10,000 tests are taken, and that 50% were for in-patients and the rest for out-patients .These 
estimates imply that in 2009, in total approximately 1.8 million INR tests were taken . Among 
those, approximately 0.5 million were taken on in-patients.  
Source: (Kristiansen I.S, report of 30.07.2010). With permission. 
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Appendix 5. Coding categories for different diagnosis  
 
ICPC-2 Coding categories for different diseases used in Norwegian health services 
 
Kapittel Tekst Symptomer og plager  Prosesskoder Sykdoms- 
diagnoser: 
A Allmenn og uspesifisert 
( General and unspecified) 
 
1-29 30-69 70-99 
B Blod, bloddannende organer og 
immunsystemet 
(Blood, blood forming organs, 
lymphatics, spleen) 
 
1-29 30-69 70-99 
D Fordøyelsessystemet 
(Digestive) 
 
1-29 30-69 70-99 
F Øye  
(Eye) 
1-29 30-69 70-99 
H Øre  
(Ear) 
1-29 30-69 70-99 
K Hjerte-karsystemet  
(Circulatory) 
1-29 30-69 70-99 
N Nervesystemet  
(Neurological) 
1-29 30-69 70-99 
P Psykisk  
(Psychological) 
1-29 30-69 70-99 
R Luftveier  
(Respiratory) 
1-29 30-69 70-99 
S Hud  
(Skin) 
1-29 30-69 70-99 
T Endokrine, metabolske, 
ernæringsforhold  
(Endocrine, metabolic and 
nutritional) 
1-29 30-69 70-99 
U Urinveier  
(Urology) 
1-29 30-69 70-99 
W Svangerskap, fødsel, 
familieplanlegging  
(Pregnancy, childbirth, family 
planning) 
1-29 30-69 70-99 
X Kvinnelige kjønnsorganer (inkl. 
bryst) 
(Female genital system and breast) 
1-29 30-69 70-99 
Y Mannlige kjønnsorganer  
(Male genital system) 
1-29 30-69 70-99 
Z Psykososiale og sosiale problemer  
(Social problems) 
1-29   
     
L Muskel-skjelettsystemet  
(Muscular and skeletal) 
1-29 30-6 70-99 
Source: Kompetansesenter for IKT i helse- og sosialsektoren AS (www.KITH.no) 
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Cardiovascular disease_ICPC-2 Coding  
 
ICPC-2 coding categories for different cardiovascular diseases. 
K29 Cardiovascular Symptom/ Complaint other  
K74 Ischaemic Heart Disease with Angina 
 
K76 Atherosclerotic Heart Disease 
K78 Atrial Fibrillation 
K80 Cardiac Arrhythmia 
K83 Heart Valve Disease 
K84 Heart Disease/ Other 
K89 Transient Cerebral Ischemia 
K90 Stroke/ cerebral embolism/infarction/thrombosis/occlusion/ 
stenosis/hemorrhage 
K92 Atherosclerosis/ Peripheral Vascular Disease 
K93 Thromboembolism/Lung/ Pulmonary Embolism 
K93 Portal Thrembosis/ superficial Deep Vein Thrombosis 
 
Source: Kompetansesenter for IKT i helse- og sosialsektoren AS (www.KITH.no) 
http://www.legemiddelsiden.no/default.aspx?PageID=706&ReportID=56&field=ICPC_Code
&Value=F 
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Appendix 6. Calculations of Reductions in INR test GPs/ private specialist Visits per 
patient per year_Norway_2009-2011 
 
Year INR – 
Users 
Norway 
2009-
2013 
INR-tests 
at GPs or 
private 
specialists 
INR –
tests  
Per 
warfarin-
user 
INR-tests 
with atrial 
fibrillation 
as main 
diagnosis 
INR-tests 
 with 
atrial 
fibrillation  
as main 
diagnosis- 
per user 
INR –tests  
Per 
warfarin-
user 
without 
atrial 
fibrillation 
Visits  
with  
NOAC 
Reduction 
in visits 
2009 86319 929135 10,76 378109 4,38 6,38 (At 
least) 
6,4 
3,38 
2010 88630 979100 11,04 399866 4,51 6,53 (At 
least) 
6,5 
3,51 
2011 92131 1049014 11,38 444171 4,82 6,56 (At 
least) 
6,6 
3,82 
2012 94709        
2013 87994        
2013 
Kunnskaps- 
senteret- 
estimate,  
  13    5 8 
At 
reimbursement 
application- 
Dabigatran,  
       16 
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Appendix 7.  Visit reductions costs for 2009-2011, and Total NOACs costs for 
2013 Norway 
 
Costs associated with calculating number reduced INR-tests at GPs and private specialists’ 
clinics in 2013 due to the introduction of NOACs  for the treatment of atrial fibrillation, given 
the assumption that atrial fibrillation is the patients’ main disease category,  and that patients 
using NOACs need only one control visit to their doctor per year.  
 
 Number of INR-measurements per warfarin- user =  
 Number of INR measurements/ Number of users = (H11/G11) = 10.8 
 Number of INR-measurements for patients with atrial fibrillation as main diagnosis per-user= 
INR-numbers for patients with atrial fibrillation as main diagnosis/ Number of users= 
(J11/G11)= 4.4 
 INR-numbers per  warfarin users at a GP without atrial fibrillation= 
(INR-numbers per warfarin-user)- (INR-numbers for patients with atrial fibrillation as main 
diagnosis per-user =( I 11-K11)   
 Number of GPs visits with NOACs= (INR-numbers per  warfarin users at a GP without atrial 
fibrillation) 
 Reduction in GPs visits= (Number of INR-measurements for patients with atrial fibrillation as 
main diagnosis per-user) – (1) 
 Cost per GPs visit (NOK)= 229 for 2009, 237 for 2010 and 244 for 2011 
Source: http://www.legemiddelsiden.no/default.aspx?PageID=139 
 Reduced costs per patient= (Reduction)* (Cost per GPs visit) = (N11)*(O11) 
 Total cost reductions= Reduced costs per patient (NOK) * number of users = (P11)*(G11) 
  Estimated reduced total costs by the Kunnskapsseneret = (number of users)*(estimated 
numbers of GPs visits)*(costs per visit) = (G11)*(N$14)*(O11) 
 
 Total costs for Dabigatran in 2013 (NOK) = 9175*G20 = 9175*13 879 = 127 339 825 
 Total costs for Rivaroxaban in 2013 (NOK) = 7966*G25 = 7966*13 423=  106 927 618 
 Total costs for Apixaban in 2013 (NOK) = G30*9345 =    21 119 700 
 Total costs NOACs in 2013 (NOK) =       255 387 143 
 Total costs for warfarin in 2013 (NOK) = G15*901 =    87 994* 901=  79 282 594 
 Total costs (NOACS and Warfarin) =      334 669 737 
 Reimbursement costs for Dabigatran (NOK) =  
G13*N$15*O13 =      (94 709)*(16)*(244) =      359 679 424 
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Appendix 8.  Number of Users_ Warfarin and NOACs_Total  Costs_Norway 
2009-2013 
 
Number of users of all ages, both sexes in the entire country for Warfarin, Dabigatran, 
Rivaroxaban and Apixaban, in the period 2009-2013, and total costs of these drugs in 2013 
(NOK). 
Dabigatran, Rivaroxaban and Apixaban are referred to as new oral anticoagulants (NOACs) 
Numbers of Users 
oral 
Anticoagulants 
2009 2010 2011 2012 2013 Price per 
year 
(NOK) 
Total Cost in 
2013 
(NOK) 
Warfarin 86318 88630 92131 94709 87994 901 
 
                                             
79 282 594  
 
Dabigatran 
Etexilate 
9 187 1168 4102 13879 9175 
 
127 339 825  
 
Rivaroxaban 45 191 898 1332 13423 7966 
 
106 927 618  
 
Apixaban 0 0 0 335 2260 9345 
 
 21 119 700  
 
All 3 NOACs       255 387 143 
Source: Norwegian Prescription Database 
http://www.reseptregisteret.no 
Report date: 29/05/2014 18:09 
 
 
 
 
Total costs for Dabigatran in 2013 =  =9175*   13 879    = 127 339 825 
Total costs for Rivaroxaban in 2013= 7966*  13 423  = 106 927 618 
Total costs for Apixaban in 2013= G30*9345    = 21 119 700 
Reimbursement costs for  Dabigatran= 94 709*16*244   =  359 679 424 
Costs for Warfarin =   87 994* 901    = 79 282 594 
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Appendix 9.  Reimbursement Costs Dabigatran_based on reduced visits- 
costs assumptions compared to HTA Kunnskapssenteret Report 5-2013 
 
Year Cost 
per 
visit 
 
Reduced 
costs per 
patient 
Reduced 
total costs 
based on 
calculated 
visits-
reductions 
in this 
study  
Reduced costs based on  
estimated visits- 
reductions given in the 
HTA Kunnskapssenteret 
Report 5-2013 
2009 229 774,11 66 820 139 
 
158 134 576 
 
2010 237 832,27 73 762 932 
 
168 042 480 
 
2011 244 932,34 85 89 7760 
 
179 839 712 
 
At 
reimbursement 
application- 
Dabigatran 
   359 679 424 
 
 
The formula used “in the Excel table” to calculate estimated reduced costs in the 
reimbursement application for Dabigatran: 
 G13*N$15*O13  
Where, 
a) G13:  Number of users in 2013 
b)  N$15: Reduction in the number of patients’ visits estimated by Boehringer-Ingelheim   
Pharma KG at their reimbursement application for Dabigatran 
c) 244: cost of GPs, private specialists visit in 2013 
=  92131*16*244 
=  359 679 424 NOK 
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Appendix 10.  Users of oral anticoagulants per 1000 ( 2004-2014) 
 
Period Users of oral anticoagulants/ total Users/ total pr 1000  
2004    43 596 19,1 
2005    45 524 19,9 
2006    47 168 20,4 
2007    48 922 20,9 
2008    50 322 21,2 
2009    51 726 21,5 
2010    53 315 21,8 
2011    56 355 22,7 
2012    59 809 23,8 
2013    69 479 27,2 
2014    72 165 27,9 
 
Appendix 11.  email survey 
 
 
Kjære laboratorieleder/sjefsbioingeniør 
 
 
Vi holder på med en studie der vi ønsker å beregne kostnadene ved INR-tester 
ved sykehus i Helse Sør-Øst. Disse data vil vi bruke i en helseøkonomisk 
analyse. Denne analysen er finansiert av legemiddelfirmaet Boehringer 
Ingelheim, Norge. 
 
Vi tillater oss å spørre om du kunne gi oss tall for utførte antall 
INR-tester i 2009, gjerne fordelt etter poliklinikk, inneliggende, eller 
lignende. Vi regner med at det finnes rutinestatistikk for dette og håper at 
det ikke skal koste mye tid å svare på spørsmålet. 
 
Dersom du ikke er rette person for å svare, ville vi være takknemlig for 
informasjon om hvem rette person er. 
 
På forhånd takk for hjelpen. 
 
 
Hani Murad     Ivar Sønbø Kristiansen 
Masterstudent     professor 
 
Avdeling for helseledelse og helseøkonomi, Universitetet i Oslo 
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Appendix 12.  Coagulation cascades for different NOACs 
 
 
 
Source:  
http://www.mayoclinicproceedings.org/cms/attachment/2005915879/2026339620/mmc2.pdf 
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  Appendix 13. Comparative Properties of Warfarin, Dabigatran, Rivaroxaban, and 
Apixaban 
 
 
 
Characteristic Warfarin Dabigatran Rivaroxaban Apixaban 
Target 
Vitamin K 
epoxide 
reductase 
Factor IIa (free and 
clot-bound 
thrombin) 
Factor Xa Factor Xa 
Prodrug No Yes No No 
Bioavailability 
(%) 
>95 6.5 >80 50 
Metabolism 
Hepatic, mainly 
via CYP2C9, 
CYP1A2, 
CYP3A4, 
CYP2C8, 
CYP2C18, and 
CYP2C19 
Hepatic 
Hepatic, mainly via 
CYP3A4, CYP3A5, 
and CYP2J2 
Hepatic, mainly via 
CYP3A4 with minor 
contributions from 
CYP1A2, CYP2C8, 
CYP2C9, CYP2C19, and 
CYP2J2 
Plasma protein 
binding (%) 
97 34-35 
∼92-95 (primarily 
albumin) 
87 
Half-life (h) 40 14-17 
5-9 
 
9-13 (elderly) 
10-14 
Elimination 92% renal 
80% renal 
 
20% fecal 
66% renal 
 
33% fecal 
27% renal 
 
63% fecal 
Monitoring INR adjusted Not needed Not needed Not needed 
Peak effect (h) 72-96 2 2-4 3-4 
Drug 
interactions 
CYP2C9, 
CYP1A2, and 
CYP3A4 
P-gp 
inducers/inhibitors 
CYP3A4 and P-gp 
inducers/inhibitors 
CYP3A4 and P-gp 
inducers/inhibitors 
Antidote Vitamin K None None None 
Reversal via 
hemodialysis 
No Yes No No 
 
CYP = cytochrome; INR = international normalized ratio; P-gp = P-glycoprotein 
Source: http://www.mayoclinicproceedings.org/article/S0025-6196(13)00222-X/fulltext#appsec1 (accessed 
02.05.2015) 
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Appendix 14. Oral anticoagulant therapy:  Recommended therapeutic Range 
 
 
Indication        INR 
 
Treatment of venous thrombosis     2.0–3.0 
Treatment of pulmonary embolism     2.0–3.0 
Prophylaxis of venous thrombosis (high-risk surgery)  2.0–3.0 
Prevention of systemic embolism     2.0–3.0 
Tissue heart valves       2.0–3.0 
Acute myocardial infarction     2.0–3.0 
Valvular heart disease      2.0–3.0 
Atrial fibrillation       2.0–3.0 
Bileaflet mechanical valve in aortic position   2.0–3.0 
Mechanical prosthetic valves (high risk)    2.5–3.5 
Systemic recurrent emboli      2.5–3.5 
 
Source: Hirsh J, Dalen JE, Anderson DR, Poller L, Bussey H, Ansell J, Deykin D, Brandt JT. Oral 
anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1998;114(5 
Suppl):445S–469S. 
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Appendix 15.  Number of users of Warfarin and NOACs per 1000 inhabitants between  
(2004- 2014). Rapport dato: 27.03.2015 11:50 http://www.reseptregisteret.no 
       
  Number 
of users 
Users pr 
1000 
inhabitants 
Population 
baseline 
  
B01AA03 2004    43 596     19,15   2 276 565 
2005    45 524     19,85   2 293 102 
2006    47 168     20,38   2 314 006 
2007    48 922     20,88   2 342 823 
2008    50 322     21,17   2 377 361 
2009    51 713     21,45   2 411 204 
2010    53 143     21,75   2 443 697 
2011    55 322     22,31   2 479 989 
2012    56 720     22,53   2 517 360 
2013    52 803     20,69   2 551 691 
2014    46 709     18,08   2 583 218 
B01AE07 2004     0     0,00     0 
2005     0     0,00     0 
2006     0     0,00     0 
2007     0     0,00     0 
2008     0     0,00     0 
2009     7     0,00   2 411 204 
2010     106     0,04   2 443 697 
2011     669     0,27   2 479 989 
2012    2 349     0,93   2 517 360 
2013    8 288     3,25   2 551 691 
2014    9 329     3,61   2 583 218 
B01AF01 2004     0     0,00     0 
2005     0     0,00     0 
2006     0     0,00     0 
2007     0     0,00     0 
2008     0     0,00     0 
2009     6     0,00   2 411 204 
2010     66     0,03   2 443 697 
2011     364     0,15   2 479 989 
2012     609     0,24   2 517 360 
2013    7 350     2,88   2 551 691 
2014    11 584     4,48   2 583 218 
B01AF02 2004     0     0,00     0 
2005     0     0,00     0 
2006     0     0,00     0 
2007     0     0,00     0 
2008     0     0,00     0 
2009     0     0,00     0 
2010     0     0,00     0 
2011     0     0,00     0 
2012     131     0,05   2 517 360 
2013    1 038     0,41   2 551 691 
2014    4 543     1,76   2 583 218 
Valgte søkekriterier: 
Legemiddel:  
    - B01AA03 -warfarin                                           
    - B01AE07 -dabigatran eteksilat 
    - B01AF01 -rivaroksaban 
    - B01AF02 -apixaban 
Periode: 2014, 2013, 2012, 2011, 2010, 2009, 2008, 2007, 2006, 2005, 2004 
Kjønn: Mann 
Ikke valgte søkekriterier: 
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Alder: tallene i rapporten er for alle aldre 
Bosted: tallene i rapporten er for hele landet 
 
 
 
 
Appendix 16.  Total umber of ususersof Oral anti coagulants per 1000 
inhabitants between (2004- 2014). SUMMARY OUTPUT 
 
 
 
 
 
Regression Statistics 
Multiple R 0,98456 
R Square 0,969358 
Adjusted R Square 0,961697 
Standard Error 0,169515 
Observations 6 
         ANOVA 
        
  df SS MS F 
Significance 
F 
   Regression 1 3,636121 3,636121 126,538 0,000356 
   Residual 4 0,114942 0,028735 
     Total 5 3,751063       
   
         
  Coefficients 
Standard 
Error t Stat P-value Lower 95% 
Upper 
95% 
Lower 
95.0% 
Upper 
95.0% 
Intercept 19,34166 0,122686 157,6516 9,71E-09 19,00103 19,68229 19,00103 19,68229 
X Variable 1 0,455827 0,040522 11,24891 0,000356 0,34332 0,568334 0,34332 0,568334 
         
         
         RESIDUAL OUTPUT 
  
PROBABILITY OUTPUT 
  
         Observation Predicted Y Residuals 
 
Percentile Y 
   1 19,34166 -0,19175 
 
8,333333 19,1499 
   2 19,79748 0,055099 
 
25 19,85258 
   3 20,25331 0,130386 
 
41,66667 20,3837 
   4 20,70914 0,172507 
 
58,33333 20,88165 
   5 21,16497 0,002202 
 
75 21,16717 
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Appendix 17.  Mean incremental costs and effects for new oral anticoagulants compared 
to warfarin, (dotted line represents WTP) 
 
 
 
Source: HTA-13 Report, page 48 
